Processes and intermediates for synthesis of adagraxib

By carrying out a series of reactions in the presence of alkali and polar solvents, the synthesis process of Adagrasib was successfully simplified, and the safety and effectiveness of existing KRas inhibitors were solved, and efficient and low-cost production was achieved.

CN119072477APending Publication Date: 2024-12-03MIRATI THERAPEUTICS INC

Patent Information

Application Number
CN202380035098.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-18
Filing Date
2023-04-17
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing KRas inhibitors lack safety and effectiveness in the treatment of cancer, especially for lung adenocarcinomas associated with KRas G12C mutations, which has pharmaceutical difficulties.

Method used

A new method for the synthesis of Adaglasib (MRTX849) is provided to produce the drug by performing a series of reactions in the presence of base and polar solvents, including reactions with phosgene derivatives and activators, avoiding The process flow was simplified by the use of palladium catalyst and protection steps.

Benefits of technology

The efficient synthesis of Adagrasibu is achieved, which improves separation yield and overall purity, reduces production costs, avoids the use of palladium catalysts, and simplifies process steps.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005092039360000021
    Figure BDA0005092039360000021
  • Figure BDA0005092039360000022
    Figure BDA0005092039360000022
  • Figure BDA0005092039360000023
    Figure BDA0005092039360000023
Patent Text Reader

Abstract

The invention relates to a novel synthesis route for synthesizing adagraxib. The invention also provides intermediates for use in the provided synthetic pathways.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to new and improved synthetic routes for the synthesis of adagrasib. Background Art

[0002] Kirsten Rat Sarcoma 2 viral oncogene homolog ("KRas") is a member of the small GTPase and Ras oncogene family. KRas acts as a molecular switch cycle between an inactive (GDP-bound) state and an active (GTP-bound) state to convert upstream cellular signals received from multiple tyrosine kinases into downstream effectors that regulate a wide variety of processes including cell proliferation (see, e.g., Alamgeer et al., (2013) Current Opin Pharmcol. 13:394-401).

[0003] The role of activated KRas in malignant diseases was observed more than three decades ago (e.g., see Der et al., (1982) Proc. Natl Acad. Sci. USA 79(11):3637-3640). Aberrant expression of KRas accounts for up to 20% of all cancers and oncogenic KRas mutations that stabilize GTP binding and cause constitutive activation of KRas, and downstream signaling has been reported in 25%-30% of lung adenocarcinomas (e.g., see Samatar and Poulikakos (2014) Nat Rev Drug Disc 13(12):928-942 doi:10.1038 / nrd428). Single nucleotide substitutions resulting in missense mutations at codons 12 and 13 of the KRas primary amino acid sequence account for approximately 40% of these KRas driver gene mutations in lung adenocarcinoma, with the G12C transversion being the most common activating mutation (e.g., see Dogan et al., (2012) Clin Cancer Res. 18(22):6169-6177, published online September 26, 2012. doi:10.1158 / 1078-0432.CCR-11-3265).

[0004] The well-known role of KRas in malignant diseases and the discovery of these frequent mutations of KRas in various tumor types make KRas a highly attractive target for cancer therapy by the pharmaceutical industry. Despite three decades of extensive discovery efforts to develop KRas inhibitors for the treatment of cancer, KRas inhibitors do not exhibit safety and / or efficacy sufficient to obtain regulatory approval (e.g., see McCormick (2015) Clin Cancer Res. 21(8): 1797-1801).

[0005] The KRas G12C inhibitor compound 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (also known as MRTX849 and also known as adagracib) has the following structure:

[0006]

[0007] Adaglasib is described, for example, in Example 478 of PCT application WO 2019 / 099524.

[0008] Although WO 2019 / 099524 describes methods for preparing adagrasib, there is a need in the art for new and improved synthetic routes for preparing adagrasib. Summary of the invention

[0009] In one embodiment, the present invention provides new and improved methods for preparing adagrasib.

[0010] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0011] a) in the presence of a base and a polar solvent, reacting a compound having the following structure:

[0012]

[0013] Reacts with compounds having the following structures:

[0014]

[0015] To produce a final compound of step (a) having the following structure:

[0016]

[0017] In one embodiment, step (a) is conducted at a temperature of about 20°C to about 120°C.

[0018] In one embodiment, the method further comprises step (b):

[0019] b) in the presence of an acid and a polar aprotic solvent, the final compound of step (a) is derivatized with phosgene

[0020] to produce a final compound of step (b) having the following structure:

[0021]

[0022] In one embodiment, step (b) is conducted at a temperature of about 0°C to about 120°C.

[0023] In one embodiment, the method further comprises step (c):

[0024] c) reacting the final compound of step (b) with

[0025] Reaction to produce a final compound of step (c) having the following structure:

[0026]

[0027] In one embodiment, step (c) is conducted at a temperature of about 0°C to about 120°C.

[0028] In one embodiment, the method further comprises step (d):

[0029] d) in the presence of an additive, a polar aprotic solvent and a base, reacting the final product of step (c) with an active

[0030] to produce a final compound of step (d) having the following structure:

[0031]

[0032] Where LG is a leaving group.

[0033] In one embodiment, step (d) is performed at a temperature of about -20°C to about 70°C.

[0034] In one embodiment, the method further comprises the step (e):

[0035] e) reacting the final compound of step (d) with a base in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and one or more polar aprotic solvents to produce

[0036] The final compound of step (e) has the following structure:

[0037]

[0038] In one embodiment, the method further comprises the step (f):

[0039] f) reacting the final compound of step (e) with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent in the presence of a solvent and optionally a base to produce adagrasib.

[0040] In one embodiment, step (f) is performed at a temperature of about -10°C to about 50°C.

[0041] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising

[0042] - in the presence of a solvent and optionally a base,

[0043] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0044] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0045] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reaction with a base, where LG is a leaving group, yields:

[0046] as well as

[0047] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0048] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0049] - in the presence of additives, polar aprotic solvents and bases,

[0050] React with activator

[0051] should, to produce:

[0052] Where LG is the leaving group;

[0053] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce:

[0054] as well as

[0055] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0056] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0057] - In the presence of a base and a polar aprotic solvent,

[0058] and React to produce:

[0060]

[0061] - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce:

[0062] Where LG is the leaving group;

[0063] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents,

[0064] Reacts with base to produce:

[0065] as well as

[0066] - in the presence of a solvent and optionally a base,

[0067] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0068] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0069] - In the presence of acid and polar solvent, Reacts with phosgene derivatives to produce:

[0070]

[0071] - In the presence of a base and a polar aprotic solvent,

[0072] and React to produce:

[0073]

[0074] - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce:

[0075] Where LG is the leaving group;

[0076] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents,

[0077] Reacts with base to produce:

[0079] as well as

[0080] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0081] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0082] - In the presence of a base and a polar solvent, and React to produce:

[0083]

[0084] - In the presence of acid and polar solvent, With phosgene

[0085] Biological reactions to produce:

[0086]

[0087] - In the presence of a base and a polar aprotic solvent, and React to produce:

[0088]

[0089] - in the presence of additives, polar aprotic solvents and bases,

[0090] Reacts with an activator to produce:

[0091] Where LG is the leaving group;

[0093] - in (S)-2-(piperazin-2-yl)acetonitrile or its inorganic or organic salt and one or more polar non-matter

[0094] In the presence of a sub-solvent, With alkali

[0095] React to produce:

[0096] and - in the presence of a solvent and optionally a base,

[0097] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0098] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0099] - In the presence of MeONa and MeOH, and React to produce:

[0100]

[0101] - In the presence of hydrogen chloride and 2-MeTHF, Reacts with triphosgene to produce:

[0102]

[0103] - In the presence of sodium tert-amyl alcohol and 2-MeTHF,

[0104] and React to produce:

[0105]

[0106] - In the presence of tripotassium phosphate K3PO4 and dipotassium phosphate K2HPO4,

[0107] With bis(trifluoromethanesulfonyl)aniline

[0108] React to produce:

[0109]

[0110] - In the presence of (S)-2-(piperazin-2-yl)acetonitrile dihydrochloride, 2-MeTHF and MeCN, Reacts with tripotassium phosphate to produce:

[0111] as well as

[0112] - In the presence of MeCN and propylphosphonic anhydride, Reaction with the sodium salt of 2-fluoroacrylic acid to produce adagrasib.

[0113] In another embodiment, the present invention provides an alternative route for the synthesis of adagrasib. Therefore, in one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the steps of:

[0114] a') in the presence of a base and a polar solvent,

[0115] and Reaction to produce a final compound of step (a') having the following structure:

[0116]

[0117] In one embodiment, step (a') is performed at a temperature of about 0°C to about 100°C.

[0118] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (b'):

[0119] b') reacting the final compound of step (a') with an alkylating agent or an arylating agent and a base in the presence of a polar solvent to produce the final compound of step (b') having the following structure:

[0120] wherein R is methyl, ethyl, isopropyl or benzyl.

[0121] In one embodiment, step (b') is performed at a temperature of about 20°C to about 120°C.

[0122] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (c'):

[0123] c') reacting the final compound of step (b') with an oxidizing agent in the presence of a polar aprotic solvent and optionally a catalyst and a base to produce a final compound of step (c') having the following structure:

[0124]

[0125] wherein R is methyl, ethyl, isopropyl or benzyl.

[0126] In one embodiment, step (c') is performed at a temperature of about 0°C to about 120°C.

[0127] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (d'):

[0128] d') reacting the final product of step (c') with (S)-(1-methylpyrrolidin-2-yl)methanol in the presence of a base and a polar aprotic solvent to produce the final compound of step (d') having the following structure:

[0129]

[0130] In one embodiment, step (d') is performed at a temperature of about -20°C to about 50°C.

[0131] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (e'):

[0132] e') reacting the final product of step (d') with an activating agent in the presence of a base, an additive and a polar aprotic solvent to produce a final compound of step (e') having the following structure:

[0133] Where LG is a leaving group.

[0134] In one embodiment, step (e') is performed at a temperature of about -20°C to about 70°C.

[0135] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (f'):

[0136] f') reacting the final product of step (e') with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof, and a polar aprotic solvent to produce a final compound of step (f') having the following structure:

[0137]

[0138] In one embodiment, step (f') is performed at a temperature of about 20°C to about 120°C.

[0139] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (g'):

[0140] g') reacting the final compound of step (f') with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent in the presence of a solvent and optionally a base to produce adagrasib.

[0141] In one embodiment, step (g') is performed at a temperature of about -10°C to about 50°C.

[0142] In one embodiment, the present invention provides a method for synthesizing adagrasib, which comprises reacting a solvent and optionally a base in the presence of Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0143] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0144] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof, and a polar aprotic solvent, wherein LG is a leaving group, to produce:

[0145]

[0146] - in the presence of a solvent and optionally a base,

[0147] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0148] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0149] - in the presence of a base, an additive and a polar aprotic solvent,

[0150] Reaction with activator,

[0151] to produce:

[0152] Where LG is a leaving group; with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0153]

[0154] - in the presence of a solvent and optionally a base,

[0155] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0156] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0157] - In the presence of a base and a polar aprotic solvent,

[0158] With (S)-(1-methylpyrrolidin-2-yl)

[0159] Reaction of methanol, wherein R is methyl, ethyl, isopropyl or benzyl, to produce:

[0160]

[0161] - in the presence of a base, an additive and a polar aprotic solvent,

[0162] Reacts with an activator to produce:

[0164] Where LG is the leaving group;

[0165] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0167]

[0168] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0169] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0170] - in the presence of a polar aprotic solvent and optionally a catalyst and a base, Reaction with an oxidizing agent, wherein R is methyl, ethyl, isopropyl or benzyl, to produce:

[0171]

[0172] - In the presence of a base and a polar aprotic solvent,

[0173] Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol

[0174] should, to produce:

[0175]

[0176] - in the presence of a base, an additive and a polar aprotic solvent,

[0177] React with activator

[0178] should, to produce:

[0179] Where LG is the leaving group;

[0180] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0181]

[0182] - in the presence of a solvent and optionally a base,

[0183] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0184] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0185] - In the presence of a polar solvent, Reaction with an alkylating agent or an arylating agent and a base to produce:

[0186] wherein R is methyl, ethyl, isopropyl or benzyl;

[0187] - in the presence of a polar aprotic solvent and optionally a catalyst and a base,

[0188] Reacts with an oxidizing agent to produce:

[0189] Where R is methyl, ethyl, isobutyl

[0190] Propyl or benzyl;

[0191] - In the presence of a base and a polar aprotic solvent,

[0192] Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce:

[0194]

[0195] - in the presence of a base, an additive and a polar aprotic solvent, Reacts with an activator to produce:

[0196] Where LG is the leaving group;

[0197] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0198]

[0199] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0200] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0201] In the presence of a base and a polar solvent, and Reaction to produce a final compound of step (a') having the following structure:

[0202]

[0203] - In the presence of a polar solvent, Reaction with an alkylating agent or an arylating agent and a base to produce:

[0205] Where R is methyl, ethyl, isobutyl

[0206] Propyl or benzyl;

[0207] - in the presence of a polar aprotic solvent and optionally a catalyst and a base, Reacts with an oxidizing agent to produce:

[0208] wherein R is methyl, ethyl, isopropyl or benzyl;

[0209] - In the presence of a base and a polar aprotic solvent,

[0210] Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce:

[0211]

[0212] - in the presence of a base, an additive and a polar aprotic solvent,

[0213] Reacts with an activator to produce:

[0214] Where LG is a leaving group; with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0216]

[0217] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0218] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0219] - In the presence of MeONa and MeOH,

[0220] and React to produce:

[0221]

[0222] - In the presence of methanol, Reacts with 2-iodopropane and sodium hydroxide to produce:

[0223]

[0224] - In the presence of 2-propanol, With methanol

[0225] Sodium, sodium tungstate, and hydrogen peroxide react to produce:

[0226]

[0227] - In the presence of potassium tert-butoxide and THF, Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce:

[0228]

[0229] - In the presence of tripotassium phosphate K3PO4 and dipotassium phosphate K2HPO4,

[0230] Reaction with bis(trifluoromethanesulfonyl)aniline

[0231] should, to produce:

[0232]

[0233] -make Reaction with tripotassium phosphate, (S)-2-(piperazin-2-yl)acetonitrile dihydrochloride and MeCN to yield:

[0234]

[0235] - In the presence of MeCN and propylphosphonic anhydride, Reaction with the sodium salt of 2-fluoroacrylic acid to produce adagrasib.

[0236] In another embodiment, the present invention provides novel intermediate compounds such as:

[0237]

[0238]

[0239] DETAILED DESCRIPTION

[0240] The present invention relates to novel synthetic routes for the synthesis of adagracib, as well as novel intermediates used in the provided routes.

[0241] Although there are known methods for synthesizing adagrasib (see WO 2019 / 099524), the synthesis provided by the present invention is greatly improved because it has fewer steps, provides high isolated yields and high or similar overall purity.

[0242] The new and improved synthesis of MRTX849-adagracib features five high-yielding steps, with expensive building blocks introduced late in the process.

[0243] Previous syntheses of adagrasib involved the introduction of two expensive chiral fragments back-to-back in steps one and two. With the new method, the two fragments are introduced near the end of the synthesis, thus greatly improving the cost efficiency of production.

[0244] The new route also avoids the use of protection steps—eliminating both the Boc and Cbz protecting groups—saving time and resources for their introduction and removal, making the route more environmentally friendly.

[0245] The new route avoids the major cost contributor, palladium catalysts. In previous syntheses, increasingly expensive palladium was used in 2 of the 6 steps, which significantly increased costs. The new procedure disclosed is completely free of transition metals.

[0246] definition

[0247] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. All patents, patent applications, and publications mentioned herein are incorporated by reference.

[0248] As used herein, "KRas G12C" refers to a mutant form of the mammalian KRas protein containing an amino acid substitution of cysteine ​​for glycine at amino acid position 12. The assignment of amino acid codons and residue positions for human KRas is based on the amino acid sequence identified by UniProtKB / Swiss-Prot P01116: variant p.Gly12Cys.

[0249] As used herein, "KRas G12C-associated disease or disorder" refers to a disease or disorder associated with, mediated by, or having a KRas G12C mutation. A non-limiting example of a KRas G12C-associated disease or disorder is a KRas G12C-associated cancer.

[0250] As used herein, the term "adagracib" refers to a compound having the name 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (also known as MRTX849) and having the following structure:

[0251]

[0252] Adaglasib is described, for example, in Example 478 of PCT application WO 2019 / 099524.

[0253] The term "adagracib" encompasses all chiral (enantiomers and diastereomers) and racemic forms of the compound.

[0254] In one embodiment, the term "adagracib" includes salts of the above compounds, for example, salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid and polygalacturonic acid, and salts formed with quaternary ammonium of the formula --NR+Z-, wherein R is hydrogen, alkyl or benzyl, and Z is a counterion including chloride, bromide, iodide, --O-alkyl, tosylate, methanesulfonate, sulfonate, phosphate or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, cinnamate, mandelate, benzylate and diphenylacetate).

[0255] When this application refers to a chemical compound, unless specifically stated otherwise, the compound encompasses all chiral (enantiomers and diastereomers) and racemic forms of the compound.

[0256] "LG" refers to a leaving group and has the meaning generally associated with the term "leaving group" in synthetic organic chemistry; that is, an atom or group displaceable under alkylation or nucleophilic aromatic substitution conditions. The term "leaving group" includes, but is not limited to, halogens such as chlorine and bromine; alkanesulfonyloxy such as methanesulfonyloxy and ethanesulfonyloxy; arylsulfonyloxy such as benzylsulfonyloxy and toluenesulfonyloxy; thienyloxy; dihalophosphonyloxy; tetrahalophosphane; perfluoroalkanesulfonyloxy such as trifluoromethanesulfonyloxy, and the like. The leaving group should be selected to have a lower chemical reactivity than the reactive group bromine (except, of course, when the leaving group is bromine, in which case it will have the same reactivity) to ensure proper reaction.

[0257] Unless otherwise specified herein, "R" refers to a group such as alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, carbocycle, cycloalkyl, heteroalkyl, heterocycle, aryl, aralkyl, or arylalkyl.

[0258] The term "alkyl" is intended to mean a straight or branched aliphatic group having 1 to 12 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms. Other examples of alkyl groups have 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, hexyl, etc. "C0" alkyl (as in "C0-C3 alkyl") is a covalent bond.

[0259] The term "alkenyl" is intended to mean an unsaturated straight or branched aliphatic group having one or more carbon-carbon double bonds having 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, pentenyl, and hexenyl.

[0260] The term "alkynyl" is intended to mean an unsaturated straight or branched aliphatic group having 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, with one or more carbon-carbon triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0261] As used herein, the terms "alkylene", "alkenylene" or "alkynylene" are intended to represent an alkyl, alkenyl or alkynyl group, respectively, as defined above, that is located between and used to connect two other chemical groups. Examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene and butylene. Examples of alkenylene groups include, but are not limited to, vinylene, propenylene and butenylene. Examples of alkynylene groups include, but are not limited to, ethynylene, propynylene and butynylene.

[0262] The term "carbocycle" as used herein is intended to mean a cycloalkyl or aryl moiety.

[0263] The term "cycloalkyl" is intended to represent a saturated or undersaturated monocyclic hydrocarbon radical, bicyclic hydrocarbon radical, tricyclic hydrocarbon radical or polycyclic hydrocarbon radical group having about 3 to 15 carbons, or having 3 to 12 carbons, or 3 to 8 carbons, or 3 to 6 carbons, and or 5 or 6 carbons. In certain embodiments, the cycloalkyl group is fused with an aryl, heteroaryl or heterocyclic radical group. The example of the cycloalkyl group includes but is not limited to cyclopentene-2-enone, cyclopentene-2-enol, cyclohex-2-enone, cyclohex-2-enol, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl etc.

[0264] The term "heteroalkyl" is intended to mean a saturated or unsaturated straight or branched chain aliphatic group, wherein one or more carbon atoms in the group are independently replaced by a heteroatom selected from the group consisting of O, S and N.

[0265] The term "aryl" is intended to mean, for example, a monocyclic, bicyclic, tricyclic or polycyclic aromatic moiety containing one to three aromatic rings, such as a C6-C14 aromatic moiety. Alternatively, the aryl group is a C6-C10 aryl group, or a C6 aryl group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl and fluorenyl.

[0266] The term "aralkyl" or "arylalkyl" is intended to mean a group comprising an aryl group covalently linked to an alkyl group. If an aralkyl group is described as "optionally substituted", it is intended that either or both of the aryl and alkyl moieties may independently be optionally substituted or unsubstituted. Alternatively, the aralkyl group is a (C1-C6)alkyl (C6-C10)aryl group, including but not limited to benzyl, phenethyl and naphthylmethyl. For simplicity, when writing "arylalkyl", this term and terms related thereto are intended to mean that the order of groups in the compound is "aryl-alkyl". Similarly, "alkyl-aryl" is intended to mean that the order of groups in the compound is "alkyl-aryl".

[0267] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the compound identified above and exhibits minimal or no undesirable toxicological effects. Examples of such salts include, but are not limited to, acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.) and salts formed with organic acids (such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalene disulfonic acid, and polygalacturonic acid). The compounds can also be administered in the form of pharmaceutically acceptable quaternary salts known to those skilled in the art, which specifically include quaternary ammonium salts of the formula --NR+Z-, wherein R is hydrogen, alkyl or benzyl, and Z is a counterion including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methanesulfonate, sulfonate, phosphate or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzoate and diphenylacetate).

[0268] As used herein, the term "mineral acid" (or "inorganic acid") refers to any acid derived from an inorganic compound that dissociates in water to produce hydrogen ions (H+). Non-limiting examples of mineral acids include hydrogen halides of the general formula HX (wherein X is F, Cl, Br or I), nitric acid, phosphoric acid, sulfuric acid, boric acid, and perchloric acid.

[0269] As used herein, the term "organic acid" refers to any organic compound having an acidic nature. Non-limiting examples of organic acids include sulfonic acids of the general formula RSOH (wherein R can be an alkyl, alkenyl, alkynyl, carbocycle, heterocycle, aryl and as defined above), carboxylic acids of the general formula RCO2H (wherein R can be an alkyl, alkenyl, alkynyl, carbocycle, heterocycle, aryl and as defined above) (having one or more carboxylic acid sites). Non-limiting examples of organic acids are lactic acid, acetic acid, formic acid, citric acid, oxalic acid, uric acid, malic acid and tartaric acid.

[0270] Synthesis scheme

[0271] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0272] a) in the presence of a base and a polar solvent, reacting a compound having the following structure:

[0273]

[0274] Reacts with compounds having the following structures:

[0275]

[0276] To produce a final compound of step (a) having the following structure:

[0277]

[0278] In one embodiment, step (a) is conducted at a temperature of about 20°C to about 120°C.

[0279] In one embodiment, the method further comprises step (b):

[0280] b) reacting the final compound of step (a) with a phosgene derivative in the presence of an acid and a polar aprotic solvent to produce a final compound of step (b) having the following structure:

[0281]

[0282] In one embodiment, step (b) is conducted at a temperature of about 0°C to about 120°C.

[0283] In one embodiment, the method further comprises step (c):

[0284] c) reacting the final compound of step (b) with

[0285] Reaction to produce a final compound of step (c) having the following structure:

[0286]

[0287] In one embodiment, step (c) is conducted at a temperature of about 0°C to about 120°C.

[0288] In one embodiment, the method further comprises step (d):

[0289] d) in the presence of an additive, a polar aprotic solvent and a base, reacting the final product of step (c) with an active

[0290] to produce a final compound of step (d) having the following structure:

[0291]

[0292] Where LG is a leaving group.

[0293] In one embodiment, step (d) is performed at a temperature of about -20°C to about 70°C.

[0294] In one embodiment, the method further comprises the step (e):

[0295] e) reacting the final compound of step (d) with a base in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and one or more polar aprotic solvents to produce the final compound of step (e) having the following structure:

[0296]

[0297] In one embodiment, the method further comprises the step (f):

[0298] f) reacting the final compound of step (e) with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent in the presence of a solvent and optionally a base to produce adagrasib.

[0299] In one embodiment, step (f) is performed at a temperature of about -10°C to about 50°C.

[0300] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising

[0301] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0302] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0303] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reaction with a base, where LG is a leaving group, yields:

[0304] as well as

[0305] - in the presence of a solvent and optionally a base,

[0306] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0307] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0308] - in the presence of additives, polar aprotic solvents and bases,

[0309] With activator

[0310] React to produce:

[0311] Where LG is the leaving group;

[0312] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents,

[0313] Reacts with base to produce:

[0314] as well as

[0315] - in the presence of a solvent and optionally a base,

[0316] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0317] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0318] - In the presence of a base and a polar aprotic solvent,

[0319] and React to produce:

[0321]

[0322] - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce:

[0323] Where LG is the leaving group;

[0324] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce:

[0325] as well as

[0326] - in the presence of a solvent and optionally a base,

[0327] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0328] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0329] - In the presence of acid and polar solvent, Reacts with phosgene derivatives to produce:

[0330]

[0331] - In the presence of a base and a polar aprotic solvent, and

[0332] React to produce:

[0333]

[0334] - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce:

[0335] Where LG is the leaving group;

[0336] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents,

[0337] Reacts with base to produce:

[0339] as well as

[0340] - in the presence of a solvent and optionally a base,

[0341] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0342] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0343] - In the presence of a base and a polar solvent,

[0344] and React to produce:

[0345]

[0346] - In the presence of acid and polar solvent, With Light

[0347] The gas derivatives react to produce:

[0348]

[0349] - In the presence of a base and a polar aprotic solvent, and

[0350] React to produce:

[0351]

[0352] - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce:

[0353] Where LG is the leaving group;

[0354] - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce:

[0355] as well as

[0356] - in the presence of a solvent and optionally a base,

[0357] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0358] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0359] - In the presence of MeONa and MeOH, and React to produce:

[0360]

[0361] - In the presence of hydrogen chloride and 2-MeTHF,

[0362] Reacts with triphosgene to produce:

[0363]

[0364] - In the presence of sodium tert-amyl alcohol and 2-MeTHF,

[0365] and Reaction,

[0366] produce:

[0367]

[0368] - In the presence of tripotassium phosphate K3PO4 and dipotassium phosphate K2HPO4,

[0369] Reaction with bis(trifluoromethanesulfonyl)aniline to produce:

[0370]

[0371] - In the presence of (S)-2-(piperazin-2-yl)acetonitrile dihydrochloride, 2-MeTHF and MeCN,

[0372] Reaction with tripotassium phosphate to

[0373] produce:

[0374] and - in the presence of MeCN and propylphosphonic anhydride,

[0375] Reaction with the sodium salt of 2-fluoroacrylic acid to produce adagrasib.

[0376] In another embodiment, the present invention provides an alternative route for the synthesis of adagrasib. Therefore, in one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the steps of:

[0377] a') in the presence of a base and a polar solvent, and

[0378] Reaction to produce a final compound of step (a') having the following structure:

[0379]

[0380] In one embodiment, step (a') is performed at a temperature of about 0°C to about 100°C.

[0381] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (b'):

[0382] b') reacting the final compound of step (a') with an alkylating agent or an arylating agent and a base in the presence of a polar solvent to produce the final compound of step (b') having the following structure:

[0383] wherein R is methyl, ethyl, isopropyl or benzyl.

[0384] In one embodiment, step (b') is performed at a temperature of about 20°C to about 120°C.

[0385] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (c'):

[0386] c') reacting the final compound of step (b') with an oxidizing agent in the presence of a polar aprotic solvent and optionally a catalyst and a base to produce the final compound of step (c') having the following structure:

[0387]

[0388] wherein R is methyl, ethyl, isopropyl or benzyl.

[0389] In one embodiment, step (c') is performed at a temperature of about 0°C to about 120°C.

[0390] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (d'):

[0391] d') reacting the final product of step (c') with (S)-(1-methylpyrrolidin-2-yl)methanol in the presence of a base and a polar aprotic solvent to produce the final compound of step (d') having the following structure:

[0392]

[0393] In one embodiment, step (d') is performed at a temperature of about -20°C to about 50°C.

[0394] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (e'):

[0395] e') reacting the final product of step (d') with an activating agent in the presence of a base, an additive and a polar aprotic solvent to produce a final compound of step (e') having the following structure:

[0396] Where LG is a leaving group.

[0397] In one embodiment, step (e') is performed at a temperature of about -20°C to about 70°C.

[0398] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (f'):

[0399] f') reacting the final product of step (e') with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof, and a polar aprotic solvent to produce a final compound of step (f') having the following structure:

[0400]

[0401] In one embodiment, step (f') is performed at a temperature of about 20°C to about 120°C.

[0402] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method further comprising step (g'):

[0403] g') reacting the final compound of step (f') with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent in the presence of a solvent and optionally a base to produce adagrasib.

[0404] In one embodiment, step (g') is performed at a temperature of about -10°C to about 50°C.

[0405] In one embodiment, the present invention provides a method for synthesizing adagrasib,

[0406] The method comprises reacting a solvent and optionally a base in the presence of Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0407] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0408] -make reacting with a base, (S)-2-(piperazine-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent, wherein LG is a leaving group

[0409] group, to produce:

[0410]

[0411] - in the presence of a solvent and optionally a base,

[0412] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0413] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0414] - in the presence of a base, an additive and a polar aprotic solvent, Reacts with an activator to produce:

[0415] Where LG is the leaving group;

[0416] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0417]

[0418] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0419] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0420] - In the presence of a base and a polar aprotic solvent,

[0421] Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol, wherein R is methyl, ethyl, isopropyl or benzyl, to produce:

[0422]

[0423] - in the presence of a base, an additive and a polar aprotic solvent,

[0424] Reacts with an activator to produce:

[0425] Where LG is the leaving group;

[0426] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0427]

[0428] - in the presence of a solvent and optionally a base,

[0429] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0430] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0431] - in the presence of a polar aprotic solvent and optionally a catalyst and a base,

[0432] Reaction with an oxidizing agent, wherein R is methyl, ethyl, isopropyl or benzyl, to produce:

[0433]

[0434] - In the presence of a base and a polar aprotic solvent,

[0435] With (S)-(1-methylpyrrolidin-2-yl)methyl

[0436] The alcohol reacts to produce:

[0437]

[0438] - in the presence of a base, an additive and a polar aprotic solvent,

[0439] Reacts with an activator to produce:

[0440] Where LG is the leaving group;

[0441] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0442]

[0443] - in the presence of a solvent and optionally a base,

[0444] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0445] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0446] - In the presence of a polar solvent, Reaction with an alkylating agent or an arylating agent and a base to produce:

[0447] wherein R is methyl, ethyl, isopropyl or benzyl;

[0448] - in the presence of a polar aprotic solvent and optionally a catalyst and a base, Reacts with an oxidizing agent to produce:

[0449] wherein R is methyl, ethyl, isopropyl or benzyl;

[0450] - In the presence of a base and a polar aprotic solvent, Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce:

[0451]

[0452] - in the presence of a base, an additive and a polar aprotic solvent,

[0453] Reacts with an activator to produce:

[0455] Where LG is the leaving group;

[0457] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0459]

[0460] - in the presence of a solvent and optionally a base,

[0461] Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0462] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0463] - In the presence of a base and a polar solvent, and Reaction to produce a final compound of step (a') having the following structure:

[0464]

[0465] - In the presence of a polar solvent, Reaction with an alkylating agent or an arylating agent and a base to produce:

[0467] wherein R is methyl, ethyl, isopropyl or benzyl;

[0469] - in the presence of a polar aprotic solvent and optionally a catalyst and a base,

[0470] Reacts with an oxidizing agent to produce:

[0471] wherein R is methyl, ethyl, isopropyl or benzyl;

[0472] - In the presence of a base and a polar aprotic solvent, Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce:

[0473]

[0474] - in the presence of a base, an additive and a polar aprotic solvent,

[0475] Reacts with an activator to produce:

[0476] in

[0477] LG is the leaving group;

[0478] -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce:

[0479]

[0480] - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

[0481] In one embodiment, the present invention provides a method for synthesizing adagrasib, the method comprising the following steps:

[0482] - In the presence of MeONa and MeOH, and React to produce:

[0483]

[0484] - In the presence of methanol, Reacts with 2-iodopropane and sodium hydroxide to produce:

[0485]

[0486] - In the presence of 2-propanol, Reacts with sodium methoxide, sodium tungstate, and hydrogen peroxide to produce:

[0487]

[0488] - In the presence of potassium tert-butoxide and THF,

[0489] Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce:

[0490]

[0491] - In the presence of tripotassium phosphate K3PO4 and dipotassium phosphate K2HPO4, Reaction with bis(trifluoromethanesulfonyl)aniline to produce:

[0492]

[0493] -make With tripotassium phosphate,

[0494] (S)-2-(Piperazin-2-yl)acetonitrile dihydrochloride is reacted with MeCN to produce:

[0495]

[0496] - In the presence of MeCN and propylphosphonic anhydride,

[0497] Reaction with the sodium salt of 2-fluoroacrylic acid to produce adagrasib.

[0498] In one embodiment, in step (a), the polar solvent is selected from the group consisting of dimethylacetamide (DMAc), dimethylformamide (DMF), 1,4-dioxane, tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), acetonitrile (MeCN), dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP) and an alcohol having the formula R-OH, wherein R is alkyl, allyl or aryl.

[0499] In one embodiment, in step (a), the polar solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, NMP, and an alcohol having the formula R-OH, where R can be, but is not limited to, an alkyl, allyl, or aryl group.

[0500] In one embodiment, in step (a), the polar solvent is methanol (MeOH).

[0501] In one embodiment, in step (a), the base is selected from the group consisting of methoxide, ethoxide, isopropoxide, tert-butoxide and tert-amyloxide.

[0502] In one embodiment, in step (a), the base includes, but is not limited to, one or more of the following: methoxide, ethoxide, isopropoxide, tert-butoxide, and tert-amyloxide.

[0503] In one embodiment, in step (a), the base is sodium methoxide.

[0504] In one embodiment, in step (b), the phosgene derivative is selected from the group consisting of phosgene, diphosgene, triphosgene, thiophosgene and 1,1'-carbonyldiimidazole.

[0505] In one embodiment, in step (b), the phosgene derivative includes, but is not limited to, one or more of the following: phosgene, diphosgene, triphosgene, thiophosgene, and 1,1'-carbonyldiimidazole.

[0506] In one embodiment, in step (b), the phosgene derivative is triphosgene.

[0507] In one embodiment, in step (b), the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO and NMP.

[0508] In one embodiment, in step (b), the polar aprotic solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

[0509] In one embodiment, in step (b), the polar aprotic solvent is 2-MeTHF.

[0510] In one embodiment, in step (b), the mineral acid is selected from the group consisting of hydrogen chloride, hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid.

[0511] In one embodiment, in step (b), the mineral acid includes, but is not limited to, one or more of the following: hydrogen chloride, hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid.

[0512] In one embodiment, in step (b), the mineral acid is hydrogen chloride.

[0513] In one embodiment, in step (c), the base is a bulky alkoxide selected from the group consisting of isopropoxide, tert-butoxide and tert-amyloxide.

[0514] In one embodiment, in step (c), the base is a bulky alkoxide, including but not limited to one or more of isopropoxide, tert-butoxide, and tert-amyloxide.

[0515] In one embodiment, in step (c), the base is sodium tert-amylate.

[0516] In one embodiment, in step (c), the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO and NMP.

[0517] In one embodiment, in step (c), the polar aprotic solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

[0518] In one embodiment, in step (c), the polar aprotic solvent is 2-MeTHF.

[0519] In one embodiment, in steps (d) and (e), the activating agent is selected from the group consisting of sulfonyl halides R-SO2X (wherein R is tolyl, mesityl, nitrobenzenesulfonyl, methyl, ethyl or propyl, and X is F, Cl or Br), anhydrides (trifluoromethanesulfonic anhydride and nonafluorobutanesulfonic anhydride) and organic trifluoromethanesulfonate reagents R 1 -N-Tf2 (where R 1 is phenyl, 5-chloro-2-pyridine, 2-pyridine).

[0520] In one embodiment, in steps (d) and (e), the activating agent includes, but is not limited to, one or more of the following: sulfonyl halides R-SO2X (wherein R may be, but is not limited to, tolyl, mesityl, nitrobenzenesulfonyl, methyl, ethyl or propyl, and X may be, but is not limited to, F, Cl or Br), anhydrides (trifluoromethanesulfonic anhydride and nonafluorobutanesulfonic anhydride), and organic trifluoromethanesulfonate reagents R 1 -N-Tf2 (where R 1 is phenyl, 5-chloro-2-pyridine, 2-pyridine).

[0521] In one embodiment, in step (d), the activating agent is bis(trifluoromethanesulfonyl)aniline.

[0522] In one embodiment, in steps (d) and (e), the base is an inorganic base.

[0523] In one embodiment, the inorganic base is selected from the group consisting of carbonates, bicarbonates, and phosphates (including monobasic, dibasic, and tribasic phosphates).

[0524] In one embodiment, the inorganic base includes, but is not limited to, one or more of the following: carbonates, bicarbonates, and phosphates (including monobasic, dibasic, and tribasic phosphates).

[0525] In one embodiment, the inorganic base is used with an alkali metal salt selected from the group consisting of lithium, sodium and potassium.

[0526] In one embodiment, the inorganic base is used with an alkali metal salt including, but not limited to, one or more of the following: lithium, sodium, and potassium.

[0527] In one embodiment, in step (d), the base is tripotassium phosphate and dipotassium phosphate.

[0528] In one embodiment, in steps (d) and (e), the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO and NMP.

[0529] In one embodiment, in steps (d) and (e), the polar aprotic solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

[0530] In one embodiment, in step (d), the polar aprotic solvent is MeCN.

[0531] In one embodiment, in step (e), the polar aprotic solvent is MeCN.

[0532] In one embodiment, in step (f), 2-fluoroacrylic acid may be used in neutral form, as a free acid or in ionic form (as a metal salt or an alkali metal salt).

[0533] In one embodiment, in step (f), the coupling agent is selected from the group consisting of: propylphosphonic anhydride Carbonyldiimidazole (CDI), carbodiimide (e.g., dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), ethyl-(N',N'-dimethylamino)propylcarbodiimide hydrochloride (EDC.HCl)), phosphonium ((benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP)), and uronium (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU)).

[0534] In one embodiment, in step (f), the base is an organic base.

[0535] In one embodiment, the organic base is selected from the group consisting of DIPEA, Et3N, DABCO and DBU.

[0536] In one embodiment, wherein in step (f), the base is an inorganic base.

[0537] In one embodiment, the inorganic base is selected from the group consisting of carbonates, bicarbonates and phosphates.

[0538] In one embodiment, in step (f), the solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, DCM, EtOAc, IPAc and NMP.

[0539] In one embodiment, in step (f), the solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, DCM, EtOAc, IPAc, and NMP.

[0540] In one embodiment, in steps (a') and (b'), the polar solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, NMP and an alcohol having the formula R-OH, wherein R is alkyl, allyl or aryl.

[0541] In one embodiment, in steps (a') and (b'), the polar solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, NMP, and an alcohol having the formula R-OH, where R can be, but is not limited to, an alkyl, allyl, or aryl group.

[0542] In one embodiment, in step (a'), the polar solvent is MeOH.

[0543] In one embodiment, in step (a'), the base is selected from the group consisting of methoxide, ethoxide, isopropoxide, tert-butoxide and tert-amyloxide.

[0544] In one embodiment, in step (a'), the base includes, but is not limited to, one or more of the following: methoxide, ethoxide, isopropoxide, tert-butoxide, and tert-amyloxide.

[0545] In one embodiment, in step (a'), the base is sodium methoxide.

[0546] In one embodiment, in step (b'), the alkylating agent or arylating agent is selected from the group consisting of aryl halides or alkyl halides RX (wherein R is methyl, ethyl, isopropyl or benzyl, and X is Cl, Br, I, alkyl sulfonate, aryl sulfonate, triflate or perfluorobutyl sulfonate), dialkyl sulfates and dialkyl carbonates.

[0547] In one embodiment, in step (b'), the alkylating agent or arylating agent includes, but is not limited to, one or more of the following: aryl halides, alkyl halides RX (wherein R can be, but is not limited to, methyl, ethyl, isopropyl or benzyl, and X can be, but is not limited to, Cl, Br, I, alkyl sulfonate, aryl sulfonate, triflate or perfluorobutyl sulfonate), dialkyl sulfates and dialkyl carbonates.

[0548] In one embodiment, the alkylating agent is 2-iodopropane.

[0549] In one embodiment, in step (b'), the base is an inorganic base.

[0550] In one embodiment, the inorganic base is selected from the group consisting of hydroxides, carbonates, bicarbonates, and phosphates (including mono-, di-, and tri-basic phosphates).

[0551] In one embodiment, the inorganic base includes, but is not limited to, one or more of the following: hydroxides, carbonates, bicarbonates, and phosphates (including mono-, di-, and tri-basic phosphates).

[0552] In one embodiment, the inorganic base is used with an alkali metal salt selected from the group consisting of lithium, sodium and potassium.

[0553] In one embodiment, in step (b'), the base is sodium hydroxide.

[0554] In one embodiment, in step (c'), the oxidizing agent is selected from the group consisting of peracid, potassium persulfate, bleach, hydrogen peroxide and urea hydrogen peroxide.

[0555] In one embodiment, in step (c'), the oxidizing agent includes, but is not limited to, one or more of the following: peracids (such as meta-chloroperbenzoic acid or peracetic acid), potassium persulfate, bleach, hydrogen peroxide, and urea hydrogen peroxide.

[0556] In one embodiment, in step (c'), the catalyst is selected from the group consisting of sodium tungstate, phenylphosphonic acid and methyltrioctylammonium hydrogen sulfate.

[0557] In one embodiment, in step (c'), the catalyst includes, but is not limited to, one or more of the following: sodium tungstate, phenylphosphonic acid, and methyltrioctylammonium hydrogen sulfate.

[0558] In one embodiment, in step (c'), the catalyst is sodium tungstate.

[0559] In one embodiment, in step (c'), the base is selected from the group consisting of methoxide, ethoxide, isopropoxide, tert-butoxide and tert-amyloxide.

[0560] In one embodiment, in step (c'), the base includes, but is not limited to, one or more of the following: methoxide, ethoxide, isopropoxide, tert-butoxide, and tert-amyloxide.

[0561] In one embodiment, in step (c'), the ammonium salt or alkali metal salt is selected from the group consisting of lithium, sodium and potassium.

[0562] In one embodiment, in step (c'), the ammonium salt or alkali metal salt includes, but is not limited to, one or more of the following: lithium, sodium, and potassium.

[0563] In one embodiment, in step (c'), the base is sodium methoxide.

[0564] In one embodiment, in step (c'), the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, 2-propanol and NMP.

[0565] In one embodiment, in step (c'), the polar aprotic solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, 2-propanol, and NMP.

[0566] In one embodiment, in step (d'), the base is a bulky alkoxide selected from the group consisting of isopropoxide, tert-butoxide and tert-amyloxide.

[0567] In one embodiment, in step (d'), the base is a bulky alkoxide, including but not limited to one or more of isopropoxide, tert-butoxide, and tert-amyloxide.

[0568] In one embodiment, in step (d'), the base is potassium tert-butoxide.

[0569] In one embodiment, in step (d'), the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO and NMP.

[0570] In one embodiment, in step (d'), the polar aprotic solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

[0571] In one embodiment, in step (d'), the polar aprotic solvent is THF.

[0572] In one embodiment, in steps (e') and (f'), the activating agent is selected from the group consisting of sulfonyl halides R-SO2X (wherein R is tolyl, mesityl, nitrobenzenesulfonyl, methyl, ethyl or propyl, and X is F, Cl or Br), anhydrides (trifluoromethanesulfonic anhydride and nonafluorobutanesulfonic anhydride) and organic trifluoromethanesulfonate reagents R 1 -N-Tf2 (where R 1 is phenyl, 5-chloro-2-pyridine, 2-pyridine).

[0573] In one embodiment, in steps (e') and (f'), the activating agent includes, but is not limited to, one or more of the following: sulfonyl halides R-SO2X (wherein R may be, but is not limited to, tolyl, mesityl, nitrobenzenesulfonyl, methyl, ethyl or propyl, and X may be, but is not limited to, F, Cl or Br), anhydrides (trifluoromethanesulfonic anhydride and nonafluorobutanesulfonic anhydride) and organic trifluoromethanesulfonate reagents R 1 -N-Tf2 (where R 1 is phenyl, 5-chloro-2-pyridine or 2-pyridine).

[0574] In one embodiment, the activating agent in step (e') and / or (f') is bis(trifluoromethanesulfonyl)aniline.

[0575] In one embodiment, in steps (e') and (f'), the base is an inorganic base.

[0576] In one embodiment, the inorganic base is selected from the group consisting of carbonates, bicarbonates, and phosphates (including monobasic, dibasic, and tribasic phosphates).

[0577] In one embodiment, the inorganic base includes, but is not limited to, one or more of the following: carbonates, bicarbonates, and phosphates (including monobasic, dibasic, and tribasic phosphates).

[0578] In one embodiment, the inorganic base is used with an alkali metal salt selected from the group consisting of lithium, sodium and potassium.

[0579] In one embodiment, the inorganic base is used with an alkali metal salt including, but not limited to, one or more of the following: lithium, sodium, and potassium.

[0580] In one embodiment, in step (e'), the inorganic base is tripotassium phosphate and dipotassium phosphate.

[0581] In one embodiment, in steps (e') and (f'), the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO and NMP.

[0582] In one embodiment, in steps (e') and (f'), the polar aprotic solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

[0583] In one embodiment, in steps (e') and (f'), the polar aprotic solvent is MeCN.

[0584] In one embodiment, in step (g'), 2-fluoroacrylic acid can be used in neutral form, as a free acid or in ionic form (as a metal salt or an alkali metal salt).

[0585] In one embodiment, in step (g'), the coupling agent is selected from the group consisting of: CDI, carbodiimide (e.g. DCC, DIC, EDC.HCl), BOP, PyBOP, HBTU, HATU.

[0586] In one embodiment, in step (g'), the base is an organic base.

[0587] In one embodiment, the organic base is selected from the group consisting of DIPEA, Et3N, DABCO and DBU.

[0588] In one embodiment, wherein in step (g'), the base is an inorganic base.

[0589] In one embodiment, the inorganic base is selected from the group consisting of carbonates, bicarbonates and phosphates.

[0590] In one embodiment, in step (g'), the solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, DCM, EtOAc, IPAc and NMP.

[0591] In one embodiment, in step (g'), the solvent includes, but is not limited to, one or more of the following: DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, DCM, EtOAc, IPAc, and NMP.

[0592] The following examples are intended to further illustrate certain embodiments of the present invention and are not intended to limit the scope of the present invention.

[0593] Example 1

[0594] Step (a)

[0595]

[0596] 1-(8-Chloronaphthalene-1-yl)-5-hydroxy-1,2,3,6-tetrahydropyridine-4-carboxylic acid methyl ester (75g, 236mmol, 1.0 equivalent) was charged into a 2L glass-lined reactor, followed by thiourea (54g, 708mmol, 3 equivalents). Methanol (750mL) was then added. The reactants were stirred at 20°C. Sodium methoxide (34g, 590mmol, 2.5 equivalents) was added to the reactants at 20°C in one go. After this, the reactants were reacted at 60°C until the area of ​​the starting material was ≤1.0 area% (approximately 4 hours). The mixture was then cooled to 20°C and purified water (750mL) was added. The mixture was filtered through a diatomaceous earth pad and transferred to a Crane reactor. 2N hydrochloric acid solution was slowly added to the reactants at 15°C to 25°C until pH = 4-5. A large amount of precipitation was observed when the hydrochloric acid solution was added. The solid was then filtered off and re-slurried with purified water (375 mL) before filtering a second time. The solid was dried at T≤45°C under a nitrogen stream and low vacuum until constant weight. 7-(8-Chloronaphthalen-1-yl)-2-thioxo-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4(1H)-one was obtained as a light yellow solid (77 g, 225 mmol, 95% yield).

[0597] Mp: 237.5℃ to 237.6℃(degrees).

[0598] 1H NMR(500MHz,DMSO-d6)δppm 2.35(br d,J=16.4Hz,1H),2.51-2.59(m,1H),3.05-3.16(m,1H),3.36-3.45(m,1H),3.57(br d,J=17.0Hz,1H),3.94(d,J=17.5Hz,1H),7.27-7.36(m,1H),7.39-7.48(m,1H),7.53(t,J=7.9 Hz,1H),7.59(dd,J=7.4,1.4Hz,1H),7.74(d,J=7.7Hz,1H),7.85-7.96(m,1H),11.68-12.50(br s,1H).

[0599] 13 C NMR(126MHz,DMSO-d6)δppm 21.6,49.7,53.5,109.8,119.7,125.5,126.5,127.3,129.1,129.3,130.1,137.5,148.3,150.1,161.9,172.9,174.9.

[0600] C 17 H 15 HRMS (ESI) calculated value of CIN3OS: 344.0624 [M+H] + , measured value: 344.0779.

[0601] Example 2

[0602] Step (b)

[0603]

[0604] 7-(8-Chloronaphthalen-1-yl)-2-thioxo-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4(1H)-one (10 g, 29 mmol, 1.0 equiv) was loaded into a 400 mL EasyMax reactor followed by 2-MeTHF (200 mL). The reactants were stirred at 25°C. A 4N solution of hydrogen chloride in dioxane (7.3 mL, 29 mmol, 1.0 equiv) was then loaded. Triphosgene (8.6 g, 29 mmol, 1.0 equiv) was added to the reactants at 25°C. After this, the reactants were reacted at 25°C until the area of ​​the starting material was ≤0.5 area % (approximately 24 hours). The mixture was then cooled to 15°C and purified water (50 mL) was added. Under stirring, a 1N sodium hydroxide solution was slowly added to the reactants at 15°C to 25°C until pH = 5-6. After this, the mixture was stirred at a temperature of 15 ° C for 10 minutes, and each layer was allowed to settle before separation. The aqueous phase was discarded, and the organic phase was concentrated until the solution volume was about 30 mL. Heptane (50 mL) was then added, and the volatiles were then removed from the slurry. The solid was dried under nitrogen flow and low vacuum at T≤45 ° C until constant weight. 2-chloro-7-(8-chloronaphthalene-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one was obtained as a yellow solid (8.5 g, 25 mmol, 85% yield).

[0605] Mp: 200.7℃ to 200.8℃(degrees).

[0606] 1 H NMR(500MHz,DMSO-d6)δppm 2.54(br s,1H),2.71-2.85(m,1H),3.11(br s,1H),3.44-3.52(m,1H),3.82(m,1H),3.99(m,1H),7.33-7.37(m,1H),7.44(t,J=7.7Hz,1H),7.53(t,J= 7.9Hz, 1H), 7.57 (dd, J = 7.4, 1.4Hz, 1H), 7.74 (d, J = 7.7Hz, 1H), 7.91 (dd, J = 8.2, 1.1Hz, 1H), 13.39 (m, 1H).

[0607] 13 C NMR(126MHz,DMSO-d6)δppm 164.5,151.3,148.3,147.4,137.5,130.1,129.3,129.1,127.3,126.4,125.5,125.4,119.5,104.4,57.1,49.8,22.3.

[0608] C 17 H 14 HRMS (ESI) calculated value for Cl2N3O: 346.0514 [M+H] + , found: 346.0668.

[0609] Example 3

[0610] Step (c)

[0611]

[0612] 2-Chloro-7-(8-chloronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one (100 mg, 0.29 mmol, 1 equiv) was charged into an 8 mL vial, followed by 2-MeTHF (1.0 mL). The reactants were stirred at 20 °C. Then (S)-(1-methylpyrrolidin-2-yl)methanol (41 μL, 0.35 mmol, 1.2 equiv) was added. Then sodium tert-pentoxide (160 mg, 0.87 mmol, 5.0 equiv) was added to the reaction mixture. Thereafter, the reactants were reacted at 60 °C until the starting material area ≤ 0.5 area% (ca. 16 h). The mixture was cooled to 20 °C and 1.0 mL of 10% w / w aqueous citric acid was added to the reaction mixture. The organic phase was discarded, and the aqueous phase was further washed with 0.5 mL of 2-MeTHF. The organic phase was discarded again, and 1.0 mL of fresh 2-MeTHF was added, and then the pH of the aqueous solution was adjusted to neutral (6.5 < pH < 7.5). The organic phase was set aside while the neutral aqueous phase was back-extracted with fresh 0.5 mL of 2-MeTHF. The combined organic phases were concentrated to half, then 1.0 mL of heptane was added. After removal of the volatiles, the solid was dried under a nitrogen stream and low vacuum at T ≤ 45 °C until constant weight. (S)-7-(8-Chloronaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one was obtained as a pale beige solid (107 mg, 0.25 mmol, 87% yield).

[0613] M.p.: 140.9 °C to 141.0 °C.

[0614] 1H NMR(500MHz,DMSO-d6)δppm 1.51-1.61(m,1H),1.66(br d,J=8.2Hz,2H),1.84-1.94(m,1H),2.14-2.25(m,1H),2.33(s,3H),2.42(m,1H),2.52-2.60(m,1H ),2.62-2.72(m,1H),2.90-2.98(m,1H),3.01-3.09(m,1H),3.42-3.48(m,1H),3.63-3.70(m,1H), 3.88(d,J=17.0Hz,1H),4.16-4.27(m,2H),7.34(d,J=7.1Hz,1H),7.40-7.46(m,1H),7.51(t,J=7. 9Hz,1H),7.57(dd,J=7.4,1.4Hz,1H),7.72(d,J=7.7Hz,1H),7.90(dd,J=8.2,1.1Hz,1H),12.2(br s,1H).

[0615] 13 C NMR(126MHz,DMSO-d6)δppm 163.6,157.8,156.0,148.6,137.6,130.0,129.4,129.0,127.3,126.4,125. 5,125.1,119.2,112.4,69.6,63.7,57.5,57.3,50.4,41.6,28.4,23.1,22.2.

[0616] C 23 H 26 HRMS (ESI) calculated value of CIN4O2: 425.1744 [M+H] + , measured value: 425.1902.

[0617] Example 4

[0618] Steps (d) and (e)

[0619]

[0620] (S)-7-(8-Chloronaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one (3.0 g, 7.06 mmol, 1 eq), tripotassium phosphate (3.0 g, 14.12 mmol, 2 eq) and dipotassium phosphate (1.2 g, 7.06 mmol, 1 eq) were charged into a 100 mL reactor followed by MeCN (30.0 mL). The reactants were stirred at 0° C. and bis(trifluoromethanesulfonyl)aniline (4.5 g, 12.71 mmol, 1.8 eq) was slowly added to the reaction mixture. After this, the reactants were reacted at 0° C. until the area of ​​the starting material was ≤5 area % (approximately 24 hours). Then, potassium phosphate (1.5 g, 7.06 mmol, 1 eq.) was added to the same mixture, followed by (S)-2-(piperazine-2-yl)acetonitrile dihydrochloride (g, 8.47 mmol, 1.2 eq.). After this, the reactants were reacted at 20 °C until the triflate intermediate area was ≤0.5 area % (approximately 16 hours). 30.0 mL of water was added to the mixture. Phase separation was performed, and the organic phase was concentrated to dryness and then diluted with 9.0 mL of DMAc. 3.0 mL of water was then added, and the mixture was seeded with the final crystalline product (1% w / w). The mixture was stirred for 10 hours, and then 9.0 mL of water was slowly added over 3 hours. The slurry was stirred at room temperature until the determination of the supernatant was ≤1 area %. The crystalline solid was then filtered, washed with 6.0 mL of water, and the solid was then dried at T≤45 °C under a nitrogen stream and low vacuum until constant weight and KF NMT 10%. 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile was obtained as an off-white solid (2.6 g, 4.94 mmol, 70% yield).

[0621] Mp: 60.3℃ to 60.4℃.

[0622] 1H NMR(400MHz,DMSO-d6)δppm 1.52-1.73(m,3H),1.84-1.96(m,1H),2.13(q,J=8.7Hz,1H),2.32(d,J=1. 8Hz,3H),2.44-2.49(m,1H),2.61-2.83(m,5H),2.85-2.98(m,3H),3.07(br s,3H),3.37(br s,2H),3.42-3.51(m,1H),3.72(s,1H),3.85(br d,J=12.4Hz,1H)4.01(ddd,J=10.5,6.7,3.3Hz,1H),4.17(br d,J=17.4Hz,1H),4.24(dd,J=10.7,4.9Hz,1H)7.31(ddd,J=7.6,3.4,0.9Hz,1H),7.43(t,J=7.8Hz ,1H),7.52(t,J=7.7Hz,1H),7.57(dd,J=7.6,1.3Hz,1H),7.72(d,J=8.1Hz,1H),7.87-7.95(m,1H).

[0623] 13 C NMR(101MHz,DMSO-d6)δppm 21.2,22.5,25.6,28.5,41.2,44.6,47.6,50.0,51.0,51.6,56.9,58.6,63.4,68.7,108.2,118. 7,118.8,124.6,124.9,125.9,126.8,128.5,128.8,129.5,137.0,148.0,162.1,163.8,165.6.

[0624] C 29 H 35 HRMS (ESI) calculated value of CIN7O: 532.2592 [M+H] + , measured value: 532.2706.

[0625] Example 5

[0626] Step (f)

[0627]

[0628] Acetonitrile (1093.0kg) is added to a 3000L glass-lined reactor. Next, MR84916 (81.6kg, 68.1kg, 128.0mol, 1.0 equivalent) is added to the reactor. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature lower than ≤45°C until 3 volumes to 4 volumes (204L to 272L) remain. Then acetonitrile (268.0kg) is added to the mixture at a temperature lower than 45°C. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature lower than 45°C until 3 volumes to 4 volumes (204L to 272L) remain. The mixture is sampled to confirm that the water content is less than 0.3% (actual 0.1%), as determined by Karl Fischer analysis. The mixture is cooled to a temperature between 10°C and 25°C (actual 16.5°C). Acetonitrile (163.9kg) was added to a separate 3000L Hastelloy reactor. The mixture was sampled to confirm that the water content was less than 0.3% (actual 0.02%). At a temperature between 10°C and 20°C, under the protection of nitrogen, sodium 2-fluoroacrylate (25.0kg, 218mol, 1.7 equivalents) was added to the Hastelloy reactor. It was confirmed that sodium 2-fluoroacrylate was in fine powder form before addition. The reactor wall was rinsed with acetonitrile (13.7kg). At a temperature between 10°C and 20°C, under the protection of nitrogen, a solution of 50 weight / weight % propylphosphonic anhydride in ethyl acetate (124.7kg, 192mol, 1.5 equivalents) was added to the sodium 2-fluoroacrylate solution in the Hastelloy reactor. The mixture was stirred for not less than 2 hours at a temperature between 10°C and 20°C. At a temperature between 10°C and 20°C, the mixture containing MR84916 in the 3000L glass-lined reactor was slowly added to the mixture containing 2-fluoroacrylate in the 3000L Hastelloy reactor. The 3000L glass-lined reactor containing MR84916 was rinsed with acetonitrile (18.2kg) and transferred to the Hastelloy reactor together with the acrylate. The reaction was carried out at 10°C to 20°C (14.5°C to 18.0°C), and after 1 hour, the mixture was sampled every 1 hour to 3 hours for HPLC purity analysis until the area % of MR84916 / (MR84916+MRTX849) was less than 0.4% (0.3% was observed at 5 hours and 1 minute). At a temperature between 10°C and 30°C, the mixture was adjusted to pH 8 to 9 with a potassium carbonate solution (348.3kg) prepared from potassium carbonate (41.6kg) and purified water (307.2kg). The mixture was continued to stir for an additional 0.5 hour and then the solution pH was retested to confirm (actual pH 8). The mixture was adjusted to a temperature of 25°C to 35°C, stirring was stopped, and the layers were allowed to settle before separation. The aqueous phase was removed and retained.At a temperature of 25°C to 35°C, the phase is washed with a solution of tripotassium phosphate prepared from tripotassium phosphate (50.1kg) and purified water (204.4kg). At a temperature of 25°C to 35°C, the mixture is stirred for another 0.5 to 3 hours, and allowed to settle, and then separated. The aqueous phase is removed and retained. The aqueous layers are combined and extracted with 2-MeTHF (175.9kg). The mixture is stirred for another 20 to 30 minutes, and each layer is allowed to settle, and then separated at a temperature between 25°C and 35°C. The organic fractions are combined, and the combined mixture is then concentrated under reduced pressure (P≤-0.06MPa) at a temperature of ≤45°C until 2 to 3 volumes (136L to 204L) remain. Isopropyl alcohol (429.2kg) is added to the mixture at a temperature of ≤45°C. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature of ≤45°C until 2 volumes to 3 volumes (136L to 204L) remain. Isopropanol (320.1kg) is added to the mixture at a temperature of ≤45°C. The mixture is circulated through the CUNO filtration system. Isopropanol (106.9kg) is then used to rinse the CUNO filter and isopropanol is added to the reactor. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature of ≤45°C until 4.5 volumes to 5.5 volumes (306L to 374L) remain. The mixture is sampled to confirm that the residual acetonitrile residue is less than 1.5% (actual 0.05%). The mixture is adjusted to a temperature of 33°C to 38°C (actual 35.3°C). Purified water (170.0kg) is added to the mixture at 33°C to 38°C. Form 2 seed crystals (0.2kg) are added to the mixture at a temperature between 33°C and 38°C. The mixture is kept at this temperature and stirred for 2 to 3 hours. The mixture is slowly cooled to 15°C to 20°C. The mixture is kept at this temperature and stirred for 6 to 10 hours. Purified water (170.0kg) is added to the reactor at a temperature of 15°C to 20°C. The mixture is slowly cooled to -3°C to 7°C (actual 4.8°C). The material is stirred to crystallize at -3°C to 7°C, and after 8 hours, the mixture is sampled every 3 to 5 hours until the mother liquor of MRTX849 is determined to be less than 0.7% by weight or the difference between two consecutive samples is ≤0.1% by weight (0.7% by weight is observed). The mixture is filtered with a stainless steel centrifuge. Purified water (102.6kg) and isopropanol (16.4kg) are added to a 3000L Hastelloy lined reactor and then transferred to a stainless steel centrifuge to rinse the filter cake. The wet cake was purged with nitrogen for 6 to 8 hours and dried in a rotary cone dryer at T≤40°C until the water content did not exceed 1% as determined by Karl Fischer analysis. After drying, the solid was cooled to 20 to 30°C. Isopropanol (368.4 kg) was added to a 1000 L glass-lined reactor and the agitator was started.The solids from the filter cake were added to a 1000L reactor and the mixture was heated to a temperature between 55°C and 60°C (actually 57.2°C). The mixture was maintained at this temperature and stirred until the solids were completely dissolved by visual inspection. The mixture was then filtered into a 1000L Hastelloy reactor (preheated to T by a filtration system heated to 55°C to 60°C). 夹套 =55 ℃ to 60 ℃). The mixture is maintained at 55 ℃ to 60 ℃. N-heptane (80.5kg) is added to the reactor and first rinsed through a filter. The mixture is stirred in the reactor for 0.5 hours. After the solid is completely dissolved, the mixture is cooled to a temperature of 43 ℃ to 47 ℃. By adding isopropanol (5.5kg) and n-heptane (1.3kg) to a 20L four-necked flask through a capsule filter, and then adding Form 2 seeds (MRTX849 Form 2, 0.8kg) maintained at a temperature between 20 ℃ and 25 ℃, a seed slurry is prepared. The mixture is stirred until uniformly mixed and then recycled through a wet mill. Before the slurry feed is added to the reactor, the reactor is checked to confirm that MRTX849 is completely dissolved and no precipitation occurs. Thereafter, Form 2 seed slurry is added to a 1000L Hastelloy reactor at a temperature between 43 ℃ and 47 ℃. The mixture is stirred for 3 to 4 hours at 43 ℃ to 47 ℃. The mixture is then cooled to a temperature of 28°C to 32°C and stirred at this temperature (actual 30.6°C) for 4 to 5 hours. Thereafter, the mixture is cooled to 18°C ​​to 22°C and stirred for 4 to 5 hours (actual 20.9°C). The mixture is then cooled to -3°C to 7°C (actual 3.5°C) under stirring. After 12 hours, the supernatant of the mixture is sampled every 3 to 5 hours to check the measured weight % of MRTX849 in the mother liquor, and confirm when the level does not exceed 1.2%, or when the difference between the samples is equal to or less than 0.2%. During crystallization, nitrogen is bubbled intermittently through the bottom port of the reactor. When checking the mother liquor, it is found that the measured weight % of MRTX849 is 1.0%. The mixture is recirculated through the wet mill at -3°C to 10°C, and the batch temperature can be expected to increase by 2°C to 3°C during this process. The solid is sampled to obtain the particle size until D(90) does not exceed 100 μm (actual 22 μm). The mixture was maintained at -3°C to 7°C for 0.5 to 1 hour. The mixture was then filtered through a stainless steel Nutsche filter. The reactor walls were rinsed with a mixed solvent system of n-heptane (15.9 kg) and isopropanol (74.1 kg) through a liquid material filter. The wet mill was then rinsed with these rinses, which were transferred to the reactor and then discharged into the filter to rinse the filter cake. The above operation was repeated once more with a mixed solvent of n-heptane (15.9 kg) and isopropanol (74.2 kg). Due to the small particle size of the wet mill, it was noted that the filtration was very slow. At T夹套 =20°C to 30°C with nitrogen to purge the solids in the filter for 8 to 10 hours, then at T 夹套 =35 ℃ to 45 ℃ place drying, until isopropanol residue does not exceed 6300ppm (actual 3488ppm) and n-heptane residue does not exceed 3500ppm (not detected, LOD 432ppm), as measured by GC.After drying is complete, the solid is cooled to a temperature between 20 ℃ and 30 ℃.The solid is sieved until the appearance of the product is uniform and there is no agglomeration.The working area RH% should not exceed 50%.The product (MRTX849) is obtained as an off-white solid (51.1kg, 50.0kg corrected for the measured weight %, 100.4 measured weight %, 64.7% yield).

[0629] Mp: 128.3℃ to 128.4℃.

[0630] 1 H NMR (400MHz, DMSO-d6) δppm 1.56-1.77(m,3H),1.96(br dd,J=11.9,7.6Hz,1H),2.20(dd,J=8.2,2.4Hz,1H),2 37(d,J=3.5Hz,3H),2.72(br d,J=1.8Hz,1H),2.91-3.03(m,2H),3.04-3.23(m,4H),3.28(br del,J=13.8,3.7Hz,1H),3.33-3.63(m,4H),3.73-3.86(m,1H),3.89-3. 98(m,1H),3.99-4.15(m,3H),4.17-4.36(m,2H),5.22-5.41(m,1H),5.4 2-5.50(m,1H),7.34-7.44(m,1H),7.46-7.53(m,1H),7.58(q,J=7.6Hz, 1H),7.63(dt,J=7.5,1.1Hz,1H),7.75-7.83(m,1H),7.93-8.00(m,1H).

[0631] 13C NMR(101MHz,DMSO-d6)δppm 22.5,25.0,25.3,25.5,26.8,28.5,41.2,47.5,50.0,57.0,58.4,58.7,63.4,68.9,99.5,108.6,118.1,118.8,124.7,124 .9,125.9,126.9,128.5,128.9,129.5,137.0,148.0,155.5(d,J=266.39Hz),161.0(d,J-11.71Hz),162.0,164.3,165.9.

[0632] 19 F NMR (376MHz, DMSO-d6) δppm-106.4.

[0633] C 32 H 36 HRMS (ESI) calculated value of ClFN7O2: 604.2603 [M+H] + , measured value: 604.2690.

[0634] Example 6

[0635] Optional Isolation of MRTX849 as Tartrate Salt:

[0636] 3.5L of ethanol was added to a reactor equipped with MRTX849 (875g), and stirred until completely dissolved. In a separate reactor, 1M L-tartaric acid THF solution was prepared by adding 1.59L of THF and 0.24kg of L-tartaric acid, and heated to 35°C to 40°C. The tartaric acid solution prepared above was added to the ethanol reaction mixture of MRTX849 at 45°C to 50°C. MRTX849 free base seed (60mg) was added at 45°C to 50°C, and precipitation was slowly observed to form. The slurry was stirred at 45°C to 50°C for at least 1 hour, then filtered, washed with cold ethanol, and vacuum dried at 40°C for 24 hours.

[0637] Example 7

[0638] Step (a')

[0639]

[0640] 1-(8-Chloronaphthalene-1-yl)-5-hydroxy-1,2,3,6-tetrahydropyridine-4-carboxylic acid methyl ester (75g, 236mmol, 1.0 equivalent) was charged into a 2L glass-lined reactor, followed by thiourea (54g, 708mmol, 3 equivalents). Methanol (750mL) was then added. The reactants were stirred at 20°C. Sodium methoxide (34g, 590mmol, 2.5 equivalents) was added to the reactants at 20°C in one go. After this, the reactants were reacted at 60°C until the area of ​​the starting material was ≤1.0 area% (approximately 4 hours). The mixture was then cooled to 20°C and purified water (750mL) was added. The mixture was filtered through a diatomaceous earth pad and transferred to a Crane reactor. 2N hydrochloric acid solution was slowly added to the reactants at 15°C to 25°C until pH = 4-5. A large amount of precipitation was observed when the hydrochloric acid solution was added. The solid was then filtered off and re-slurried with purified water (375 mL) before filtering a second time. The solid was dried at T≤45°C under a nitrogen stream and low vacuum until constant weight. 7-(8-Chloronaphthalen-1-yl)-2-thioxo-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4(1H)-one was obtained as a light yellow solid (77 g, 225 mmol, 95% yield).

[0641] Mp: 237.5℃ to 237.6℃(degrees).

[0642] 1 H NMR(500MHz,DMSO-d6)δppm 2.35(br d,J=16.4Hz,1H),2.51-2.59(m,1H),3.05-3.16(m,1H),3.36-3.45(m,1H),3.57(br d,J=17.0Hz,1H),3.94(d,J=17.5Hz,1H),7.27-7.36(m,1H),7.39-7.48(m,1H),7.53(t,J=7.9 Hz,1H),7.59(dd,J=7.4,1.4Hz,1H),7.74(d,J=7.7Hz,1H),7.85-7.96(m,1H),11.68-12.50(br s,1H).

[0643] 13 C NMR(126MHz,DMSO-d6)δppm 21.6,49.7,53.5,109.8,119.7,125.5,126.5,127.3,129.1,129.3,130.1,137.5,148.3,150.1,161.9,172.9,174.9.

[0644] C 17 H15 HRMS (ESI) calculated value of CIN3OS: 344.0624 [M+H] + , measured value: 344.0779.

[0645] Example 8

[0646] Step (b')

[0647]

[0648] 7-(8-Chloronaphthalen-1-yl)-2-thioxo-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4(1H)-one (10 g, 29.0 mmol, 1.0 equiv) was charged into a 250 mL 3-neck round bottom flask. MeOH (100 mL) was then added. 1 N aqueous sodium hydroxide solution (77 mL, 77.0 mmol, 2.66 equiv) was then added.

[0649] Stirring is continued until a uniform solution is obtained. Then 2-iodopropane (5.2mL, 50.0mmol, 1.7 equivalents) is added to the solution. After this, the reactant is reacted at 40°C until the starting material area is ≤3.0 area % (about 36 hours). The reaction mixture is cooled to 5°C and 2N HCl aqueous solution (45mL, 90mmol, 3 equivalents) is slowly added. The solid formed when added is then collected by filtration and washed with water (100mL). The solid is dried until constant weight to obtain 7- (8- chloronaphthalene -1- bases) -2- (isopropylthio) -5,6,7,8- tetrahydropyrido [3,4-d] pyrimidine -4 (3H) -one, which is an off-white solid (9.6g, 24.7mmol, 85% yield).

[0650] Mp: 225.8℃ to 225.9℃.

[0651] 1H NMR (400MHz, DMSO-d6) δ12.62(s,1H),7.91(dd,J=8.2,1.3Hz,1H),7.73(dd,J=8.2,1.1Hz,1H),7.58(dd ,J=7.5,1.3Hz,1H),7.52(t,J=7.8Hz,1H),7.44(t,J=7.8Hz,1H),7.36(dd,J=7.6,1.2Hz,1H),3.96(d,J= 17.1Hz,1H),3.86(hept,J=6.9Hz,1H),3.73(dt,J=17.1,2.1Hz,1H),3.45(dd,J=12.5,5.5Hz,1H),3.06 (ddd,J=11.8,10.0,4.1Hz,1H),2.72(dt,J=15.7,7.3Hz,1H),2.46(d,J=16.7Hz,1H),1.43-1.25(m,6H).

[0652] 13 C NMR(101MHz,DMSO-d6)δ162.3,158.0,155.3,148.5,137.5,130.0,129.4,129.0 ,127.3,126.3,125.4,125.1,119.2,115.2,57.4,50.1,36.1,23.1,23.0,22.2.

[0653] C 20 H 21 HRMS (ESI) calculated value of CIN3OS: 386.1094 [M+H] + , measured value: 386.1092.

[0654] Example 9

[0655] Step (c')

[0656]

[0657] 7-(8-Chloronaphthalen-1-yl)-2-(isopropylthio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one (12 g, 31 mmol, 1.0 eq) was charged into a 250 mL 3-neck round bottom flask. MeOH (60 mL) was then added. The reaction mixture was cooled to 0 °C and sodium methoxide solution (7 mL, 34 mmol, 1.1 eq, 4.5 M in MeOH) was slowly added. Sodium tungstate (1.0 g, 3.1 mmol, 0.1 eq) was then added to the reaction mixture, followed by the slow addition of hydrogen peroxide (32 mL, 310 mmol, 10 eq, 30% aqueous solution). After this, the reactants were reacted at 20 °C until the starting material area was ≤1.0 area % (approximately 16 hours). Water (120 mL) and 2-MeTHF (120 mL) were added to the reaction mixture. The mixture was cooled to 5 ° C and 20% w / v aqueous acetic acid solution (120 mL) was slowly added. After the addition was complete, sodium carbonate was slowly added until pH = 8 (gas evolution). The aqueous phase was discarded and the organic phase was washed with brine. The organic phase was concentrated under reduced pressure and 2-MeTHF (36 mL) was added. Heptane (120 mL) was then slowly added to obtain 7- (8- chloronaphthalene -1- base) -2- (isopropylsulfonyl) -5,6,7,8- tetrahydropyrido [3,4-d] pyrimidine -4 (3H) -one as an off-white solid (12.5 g, 28.2 mmol, 91% yield) after filtering and drying.

[0658] Mp: 195.5℃ to 195.6℃.

[0659] 1 H NMR (400MHz, DMSO-d6) δ13.66(s,1H),7.92(dd,J=8.2,1.3Hz,1H),7.76(dd,J=8.3,1.1Hz,1H),7.61 -7.50(m,2H),7.45(t,J-7.8Hz,1H),7.39(dd,J=7.6,1.2Hz,1H),4.19(d,J=17.2Hz,1H),3.99(dt,J=17.4,1.8Hz,1H),3.90-3.75(m,J=6.8H z,1H),3.61-3.51(m,1H),3.20(ddd,J=12.0,10.1,4.1Hz,1H),2.97(ddd,J=16.7,10.3,6.3Hz,1H),2.74-2.65(m,1H),1.26(d,J=6.9Hz,6H).

[0660] 13C NMR(101MHz,DMSO-d6)δ168.6,163.7,160.4,148.2,137.5,130.1,129.3,129.1 ,127.3,126.4,125.4,125.4,119.4,117.8,57.5,51.0,49.8,22.8,15.1,15.0.

[0661] C 20 H 21 HRMS (ESI) calculated value of CIN3O3S: 418.0992 [M+H] + , measured value: 418.0991.

[0662] Example 10

[0663] Step (d')

[0664]

[0665] (S)-(1-methylpyrrolidin-2-yl)methanol (230mg, 2.0mmol, 2.0 equivalents) was loaded into a 20mL vial. Then THF (2.4mL) was added. The reactant was cooled to 0°C. Potassium tert-butoxide (450mg, 4mmol, 4.0 equivalents) was then added at the same temperature. 7-(8-chloronaphthalene-1-yl)-2-(isopropylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one (418mg, 1.0mmol, 1.0 equivalents) dissolved in THF (2.4mL) was slowly added at 0°C. After this, the reactant was reacted at 20°C until the starting material area was ≤1.0 area% (about 16 hours). The reaction mixture was cooled to 0°C and a solution of 10w / w%AcOH in THF (4mL) was slowly added. Methanol (4mL) was then added, and the insoluble material was filtered out. The filtrate is concentrated to remove most of the solvent and ethyl acetate (10 mL) is added. The organic phase is washed with brine, dried over MgSO4 and filtered. Volatiles are removed, and the crude product (400 mg) is stirred in n-heptane (8 mL) at 20 ° C for 16 hours. The solid product is filtered out to obtain (S)-7-(8-chloronaphthalene-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-4(3H)-one as an off-white solid (310 mg, 0.72 mmol, 72% yield).

[0666] Mp: 140.9℃ to 141.0℃.

[0667] 1H NMR(500MHz,DMSO-d6)δppm 1.51-1.61(m,1H),1.66(br d,J=8.21Hz,2H),1.84-1.94(m,1H),2.14-2.25(m,1H),2.33(s,3H),2.42(m,1H),2.52-2.60(m,1H) ,2.62-2.72(m,1H),2.90-2.98(m,1H),3.01-3.09(m,1H),3.42-3.48(m,1H),3.63-3.70(m,1H),3.8 8(d,J-16.97Hz,1H),4.16-4.27(m,2H),7.34(d,J=7.12Hz,1H),7.40-7.46(m,1H),7.51(t,J=7.94H z,1H),7.57(dd,J=7.39,1.37Hz,1H),7.72(d,J=7.67Hz,1H),7.90(dd,J=8.21,1.10Hz,1H),12.2(br s,1H).

[0668] 13 C NMR(126MHz,DMSO-d6)δppm 163.6,157.8,156.0,148.6,137.6,130.0,129.4,129.0,127.3,126.4,125. 5,125.1,119.2,112.4,69.6,63.7,57.5,57.3,50.4,41.6,28.4,23.1,22.2.

[0669] C 23 H 26 HRMS (ESI) calculated value of CIN4O2: 425.1744 [M+H] + , measured value: 425.1902.

[0670] Embodiment 11

[0671] Steps (e') and (f')

[0672]

[0673] (S)-7-(8-Chloronaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one (3.0 g, 7.06 mmol, 1 eq), tripotassium phosphate (3.0 g, 14.12 mmol, 2 eq) and dipotassium phosphate (1.2 g, 7.06 mmol, 1 eq) were charged into a 100 mL reactor followed by MeCN (30.0 mL). The reactants were stirred at 0° C. and bis(trifluoromethanesulfonyl)aniline (4.5 g, 12.71 mmol, 1.8 eq) was slowly added to the reaction mixture. After this, the reactants were reacted at 0° C. until the area of ​​the starting material was ≤5 area % (approximately 24 hours). Then, potassium phosphate (1.5 g, 7.06 mmol, 1 eq.) was added to the same mixture, followed by (S)-2-(piperazine-2-yl)acetonitrile dihydrochloride (g, 8.47 mmol, 1.2 eq.). After this, the reactants were reacted at 20 °C until the triflate intermediate area was ≤0.5 area % (approximately 16 hours). 30.0 mL of water was added to the mixture. Phase separation was performed, and the organic phase was concentrated to dryness and then diluted with 9.0 mL of DMAc. 3.0 mL of water was then added, and the mixture was seeded with the final crystalline product (1% w / w). The mixture was stirred for 10 hours, and then 9.0 mL of water was slowly added over 3 hours. The slurry was stirred at room temperature until the determination of the supernatant was ≤1 area %. The crystalline solid was then filtered, washed with 6.0 mL of water, and the solid was then dried at T≤45 °C under a nitrogen stream and low vacuum until constant weight and KF NMT 10%. 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile was obtained as an off-white solid (2.6 g, 4.94 mmol, 70% yield).

[0674] Mp: 60.3℃ to 60.4℃.

[0675] 1H NMR(400MHz,DMSO-d6)δppm 1.52-1.73(m,3H),1.84-1.96(m,1H),2.13(q,J=8.67Hz,1H),2.32(d,J=1. 77Hz,3H),2.44-2.49(m,1H),2.61-2.83(m,5H),2.85-2.98(m,3H),3.07(br s,3H),3.37(br s,2H),3.42-3.51(m,1H),3.72(s,1H),3.85(br d,J=12.38Hz,1H)4.01(ddd,J=10.48,6.69,3.28Hz,1H),4.17(br d,J=17.43Hz,1H),4 24(dd,J=10.74,4.93Hz,1H)7.31(ddd,J=7.58,3.41,0.88Hz,1H),7.43(t,J=7.83Hz,1H),7.5 2(t,J=7.71Hz,1H),7.57(dd,J=7.58,1.26Hz,1H),7.72(d,J=8.08Hz,1H),7.87-7.95(m,1H).

[0676] 13 C NMR(101MHz,DMSO-d6)δppm 21.2,22.5,25.6,28.5,41.2,44.6,47.6,50.0,51.0,51.6,56.9,58.6,63.4,68.7,108.2,118. 7,118.8,124.6,124.9,125.9,126.8,128.5,128.8,129.5,137.0,148.0,162.1,163.8,165.6.

[0677] C 29 H 35 HRMS (ESI) calculated value of CIN7O: 532.2592 [M+H] + , measured value: 532.2706.

[0678] Example 12

[0679] Step (g')

[0680]

[0681] Acetonitrile (1093.0kg) is added to a 3000L glass-lined reactor. Next, MR84916 (81.6kg, 68.1kg, 128.0mol, 1.0 equivalent) is added to the reactor. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature lower than ≤45°C until 3 volumes to 4 volumes (204L to 272L) remain. Then acetonitrile (268.0kg) is added to the mixture at a temperature lower than 45°C. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature lower than 45°C until 3 volumes to 4 volumes (204L to 272L) remain. The mixture is sampled to confirm that the water content is less than 0.3% (actual 0.1%), as determined by Karl Fischer analysis. The mixture is cooled to a temperature between 10°C and 25°C (actual 16.5°C). Acetonitrile (163.9kg) was added to a separate 3000L Hastelloy reactor. The mixture was sampled to confirm that the water content was less than 0.3% (actual 0.02%). At a temperature between 10°C and 20°C, under the protection of nitrogen, sodium 2-fluoroacrylate (25.0kg, 218mol, 1.7 equivalents) was added to the Hastelloy reactor. It was confirmed that sodium 2-fluoroacrylate was in fine powder form before addition. The reactor wall was rinsed with acetonitrile (13.7kg). At a temperature between 10°C and 20°C, under the protection of nitrogen, a solution of 50 weight / weight % propylphosphonic anhydride in ethyl acetate (124.7kg, 192mol, 1.5 equivalents) was added to the sodium 2-fluoroacrylate solution in the Hastelloy reactor. The mixture was stirred for not less than 2 hours at a temperature between 10°C and 20°C. At a temperature between 10°C and 20°C, the mixture containing MR84916 in the 3000L glass-lined reactor was slowly added to the mixture containing 2-fluoroacrylate in the 3000L Hastelloy reactor. The 3000L glass-lined reactor containing MR84916 was rinsed with acetonitrile (18.2kg) and transferred to the Hastelloy reactor together with the acrylate. The reaction was carried out at 10°C to 20°C (14.5°C to 18.0°C), and after 1 hour, the mixture was sampled every 1 hour to 3 hours for HPLC purity analysis until the area % of MR84916 / (MR84916+MRTX849) was less than 0.4% (0.3% was observed at 5 hours and 1 minute). At a temperature between 10°C and 30°C, the mixture was adjusted to pH 8 to 9 with a potassium carbonate solution (348.3kg) prepared from potassium carbonate (41.6kg) and purified water (307.2kg). The mixture was continued to stir for an additional 0.5 hour and then the solution pH was retested to confirm (actual pH 8). The mixture was adjusted to a temperature of 25°C to 35°C, stirring was stopped, and the layers were allowed to settle before separation. The aqueous phase was removed and retained.At a temperature of 25°C to 35°C, the phase is washed with a solution of tripotassium phosphate prepared from tripotassium phosphate (50.1kg) and purified water (204.4kg). At a temperature of 25°C to 35°C, the mixture is stirred for another 0.5 to 3 hours, and allowed to settle, and then separated. The aqueous phase is removed and retained. The aqueous layers are combined and extracted with 2-MeTHF (175.9kg). The mixture is stirred for another 20 to 30 minutes, and each layer is allowed to settle, and then separated at a temperature between 25°C and 35°C. The organic fractions are combined, and the combined mixture is then concentrated under reduced pressure (P≤-0.06MPa) at a temperature of ≤45°C until 2 to 3 volumes (136L to 204L) remain. Isopropyl alcohol (429.2kg) is added to the mixture at a temperature of ≤45°C. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature of ≤45°C until 2 volumes to 3 volumes (136L to 204L) remain. Isopropanol (320.1kg) is added to the mixture at a temperature of ≤45°C. The mixture is circulated through the CUNO filtration system. Isopropanol (106.9kg) is then used to rinse the CUNO filter and isopropanol is added to the reactor. The mixture is concentrated under reduced pressure (P≤-0.06MPa) at a temperature of ≤45°C until 4.5 volumes to 5.5 volumes (306L to 374L) remain. The mixture is sampled to confirm that the residual acetonitrile residue is less than 1.5% (actual 0.05%). The mixture is adjusted to a temperature of 33°C to 38°C (actual 35.3°C). Purified water (170.0kg) is added to the mixture at 33°C to 38°C. Form 2 seed crystals (0.2kg) are added to the mixture at a temperature between 33°C and 38°C. The mixture is kept at this temperature and stirred for 2 to 3 hours. The mixture is slowly cooled to 15°C to 20°C. The mixture is kept at this temperature and stirred for 6 to 10 hours. Purified water (170.0kg) is added to the reactor at a temperature of 15°C to 20°C. The mixture is slowly cooled to -3°C to 7°C (actual 4.8°C). The material is stirred to crystallize at -3°C to 7°C, and after 8 hours, the mixture is sampled every 3 to 5 hours until the mother liquor of MRTX849 is determined to be less than 0.7% by weight or the difference between two consecutive samples is ≤0.1% by weight (0.7% by weight is observed). The mixture is filtered with a stainless steel centrifuge. Purified water (102.6kg) and isopropanol (16.4kg) are added to a 3000L Hastelloy lined reactor and then transferred to a stainless steel centrifuge to rinse the filter cake. The wet cake was purged with nitrogen for 6 to 8 hours and dried in a rotary cone dryer at T≤40°C until the water content did not exceed 1% as determined by Karl Fischer analysis. After drying, the solid was cooled to 20 to 30°C. Isopropanol (368.4 kg) was added to a 1000 L glass-lined reactor and the agitator was started.The solids from the filter cake were added to a 1000L reactor and the mixture was heated to a temperature between 55°C and 60°C (actually 57.2°C). The mixture was maintained at this temperature and stirred until the solids were completely dissolved by visual inspection. The mixture was then filtered into a 1000L Hastelloy reactor (preheated to T by a filtration system heated to 55°C to 60°C). 夹套 =55 ℃ to 60 ℃). The mixture is maintained at 55 ℃ to 60 ℃. N-heptane (80.5kg) is added to the reactor and first rinsed through a filter. The mixture is stirred in the reactor for 0.5 hours. After the solid is completely dissolved, the mixture is cooled to a temperature of 43 ℃ to 47 ℃. By adding isopropanol (5.5kg) and n-heptane (1.3kg) to a 20L four-necked flask through a capsule filter, and then adding Form 2 seeds (MRTX849 Form 2, 0.8kg) maintained at a temperature between 20 ℃ and 25 ℃, a seed slurry is prepared. The mixture is stirred until uniformly mixed and then recycled through a wet mill. Before the slurry feed is added to the reactor, the reactor is checked to confirm that MRTX849 is completely dissolved and no precipitation occurs. Thereafter, Form 2 seed slurry is added to a 1000L Hastelloy reactor at a temperature between 43 ℃ and 47 ℃. The mixture is stirred for 3 to 4 hours at 43 ℃ to 47 ℃. The mixture is then cooled to a temperature of 28°C to 32°C and stirred at this temperature (actual 30.6°C) for 4 to 5 hours. Thereafter, the mixture is cooled to 18°C ​​to 22°C and stirred for 4 to 5 hours (actual 20.9°C). The mixture is then cooled to -3°C to 7°C (actual 3.5°C) under stirring. After 12 hours, the supernatant of the mixture is sampled every 3 to 5 hours to check the measured weight % of MRTX849 in the mother liquor, and confirm when the level does not exceed 1.2%, or when the difference between the samples is equal to or less than 0.2%. During crystallization, nitrogen is bubbled intermittently through the bottom port of the reactor. When checking the mother liquor, it is found that the measured weight % of MRTX849 is 1.0%. The mixture is recirculated through the wet mill at -3°C to 10°C, and the batch temperature can be expected to increase by 2°C to 3°C during this process. The solid is sampled to obtain the particle size until D(90) does not exceed 100 μm (actual 22 μm). The mixture was maintained at -3°C to 7°C for 0.5 to 1 hour. The mixture was then filtered through a stainless steel Nutsche filter. The reactor walls were rinsed with a mixed solvent system of n-heptane (15.9 kg) and isopropanol (74.1 kg) through a liquid material filter. The wet mill was then rinsed with these rinses, which were transferred to the reactor and then discharged into the filter to rinse the filter cake. The above operation was repeated once more with a mixed solvent of n-heptane (15.9 kg) and isopropanol (74.2 kg). Due to the small particle size of the wet mill, it was noted that the filtration was very slow. At T夹套 =20°C to 30°C with nitrogen to purge the solids in the filter for 8 to 10 hours, then at T 夹套 =35 ℃ to 45 ℃ place drying, until isopropanol residue does not exceed 6300ppm (actual 3488ppm) and n-heptane residue does not exceed 3500ppm (not detected, LOD 432ppm), as measured by GC.After drying is complete, the solid is cooled to a temperature between 20 ℃ and 30 ℃.The solid is sieved until the appearance of the product is uniform and there is no agglomeration.The working area RH% should not exceed 50%.The product (MRTX849) is obtained as an off-white solid (51.1kg, 50.0kg corrected for the measured weight %, 100.4 measured weight %, 64.7% yield).

[0682] Mp: 128.3℃ to 128.4℃.

[0683] 1 H NMR (400MHz, DMSO-d6) δppm 1.56-1.77(m,3H),1.96(br dd,J=11.87,7.58Hz,1H),2.20(dd,J=8.21,2.40Hz,1H),2.37(d,J=3.54Hz,3H),2.72(br d,J=1.77Hz,1H),2.91-3.03(m,2H),3.04-3.23(m,4H),3.28(br dd,J=13.77,3.66Hz,1H),3.33-3.63(m,4H),3.73-3.86(m,1H),3.89-3. 98(m,1H),3.99-4.15(m,3H),4.17-4.36(m,2H),5.22-5.41(m,1H),5.42 -5.50(m,1H),7.34-7.44(m,1H),7.46-7.53(m,1H),7.58(q,J=7.58Hz,1 H),7.63(dt,J=7.45,1.07Hz,1H),7.75-7.83(m,1H),7.93-8.00(m,1H).

[0684] 13C NMR(101MHz,DMSO-d6)δppm 22.5,25.0,25.3,25.5,26.8,28.5,41.2,47.5,50.0,57.0,58.4,58.7,63.4,68.9,99.5,108.6,118.1,118.8,124.7,124 .9,125.9,126.9,128.5,128.9,129.5,137.0,148.0,155.5(d,J=266.39Hz),161.0(d,J=11.71Hz),162.0,164.3,165.9.

[0685] 19 C NMR (376MHz, DMSO-d6) 8ppm-106.4.

[0686] C 32 H 36 HRMS (ESI) calculated value of CIFN7O2: 604.2603 [M+H] + , measured value: 604.2690.

[0687] Optional Isolation of MRTX849 as Tartrate Salt:

[0688] 3.5L of ethanol was added to a reactor equipped with MRTX849 (875g), and stirred until completely dissolved. In a separate reactor, 1M L-tartaric acid THF solution was prepared by adding 1.59L of THF and 0.24kg of L-tartaric acid, and heated to 35°C to 40°C. The tartaric acid solution prepared above was added to the ethanol reaction mixture of MRTX849 at 45°C to 50°C. MRTX849 free base seed (60mg) was added at 45°C to 50°C, and precipitation was slowly observed to form. The slurry was stirred at 45°C to 50°C for at least 1 hour, then filtered, washed with cold ethanol, and vacuum dried at 40°C for 24 hours.

[0689] Although the invention has been described in conjunction with particular embodiments thereof, it will be understood that it is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention, generally following the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the basic features set forth above and as fall within the scope of the appended claims.

Claims

1. A method for synthesizing adagracib, the method comprising the following steps: a) in the presence of a base and a polar solvent, reacting a compound having the following structure: Reacts with compounds having the following structures: To produce a final compound of step (a) having the following structure:

2. The method according to claim 1, wherein the base is selected from the group consisting of methoxide, ethoxide, isopropoxide, tert-butoxide and tert-amyloxide.

3. The method of claim 1, wherein the base is MeONa.

4. The method of claim 1, wherein the polar solvent is selected from the group consisting of dimethylacetamide (DMAc), dimethylformamide (DMF), 1,4-dioxane, tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), acetonitrile (MeCN), dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP), and an alcohol having the formula R-OH, wherein R is an alkyl, allyl, or aryl group. The method according to claim 1 , wherein the polar solvent is MeOH.

6. The method according to claim 1, further comprising step (b): b) reacting the final compound of step (a) with a phosgene derivative in the presence of an acid and a polar aprotic solvent to produce a final compound of step (b) having the following structure:

7. The method according to claim 6, wherein the phosgene derivative is selected from the group consisting of phosgene, diphosgene, triphosgene, thiophosgene and 1,1'-carbonyldiimidazole.

8. The method of claim 7, wherein the phosgene derivative is triphosgene.

9. The method of claim 6, wherein the acid is selected from the group consisting of hydrogen chloride, hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid.

10. The process of claim 9 wherein the mineral acid is hydrogen chloride.

11. The method of claim 6, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

12. The method of claim 11, wherein the polar aprotic solvent is 2-MeTHF.

13. The method according to claim 6, further comprising step (c): c) reacting the final compound of step (b) with Reaction to produce a final compound of step (c) having the following structure:

14. The method of claim 13, wherein the base is selected from the group consisting of isopropoxide, tert-butoxide, and tert-amyloxide.

15. The process of claim 14, wherein the base is tert-amyl alkoxide.

16. The method of claim 13, wherein the base is sodium tert-amylate.

17. The method of claim 13, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

18. The method of claim 17, wherein the polar aprotic solvent is 2-MeTHF.

19. The method according to claim 13, further comprising step (d): d) reacting the final product of step (c) with an activating agent in the presence of an additive, a polar aprotic solvent and a base to produce a final compound of step (d) having the following structure: Where LG is a leaving group.

20. The method according to claim 19, wherein the activating agent is selected from the group consisting of sulfonyl halides R-SO2X (wherein R is tolyl, mesityl, nitrobenzenesulfonyl, methyl, ethyl or propyl, and X is F, Cl or Br), anhydrides (trifluoromethanesulfonic anhydride and nonafluorobutanesulfonic anhydride) and organic trifluoromethanesulfonate reagents R l -N-Tf2 (where R 1 is phenyl, 5-chloro-2-pyridine, 2-pyridine).

21. The method of claim 20, wherein the activating agent is bis(trifluoromethanesulfonyl)aniline.

22. The method of claim 19, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

23. The method of claim 19, wherein the polar aprotic solvent is MeCN.

24. The method of claim 19, wherein the base is an inorganic base.

25. The method of claim 24, wherein the inorganic base is selected from the group consisting of carbonates, bicarbonates and phosphates.

26. The method of claim 25, wherein the inorganic base is tripotassium phosphate or dipotassium phosphate.

27. The method according to claim 19, further comprising step (e): e) reacting the final compound of step (d) with a base in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and one or more polar aprotic solvents to produce a final compound of step (e) having the following structure:

28. The method of claim 27, wherein the base is an organic base.

29. The method of claim 28, wherein the organic base is selected from the group consisting of DIPEA, Et3N, DABCO and DBU.

30. The method of claim 27, wherein the base is an inorganic base.

31. The method of claim 30, wherein the inorganic base is selected from the group consisting of carbonates, bicarbonates and phosphates.

32. The method of claim 27, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

33. The method of claim 33, wherein the polar aprotic solvent comprises MeCN.

34. The method according to claim 27, further comprising step (f): f) reacting the final compound of step (e) with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent in the presence of a solvent and optionally a base to produce adagrasib.

35. The method of claim 34, wherein the coupling agent is selected from the group consisting of: propylphosphonic anhydride Carbonyldiimidazole (CDI), carbodiimide (e.g., dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), ethyl-(N',N'-dimethylamino)propylcarbodiimide hydrochloride (EDC.HCl)), phosphonium ((benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP)), and uronium (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU)).

36. The method of claim 34, wherein the solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, DCM, EtOAc, IPAc, and NMP.

37. The method of claim 34, wherein the base is an organic base.

38. The method of claim 37, wherein the organic base is selected from the group consisting of DIPEA, Et3N, DABCO and DBU.

39. The method of claim 34, wherein the base is an inorganic base.

40. The method of claim 39, wherein the inorganic base is selected from the group consisting of carbonates, bicarbonates, and phosphates.

41. A method for synthesizing adagrasib, the method comprising - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

42. A method for synthesizing adagracib, the method comprising the following steps: - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce: as well as - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

43. A method for synthesizing adagracib, the method comprising the following steps: - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce: Where LG is the leaving group; - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce: as well as - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

44. A method for synthesizing adagracib, the method comprising the following steps: - In the presence of a base and a polar aprotic solvent, and React to produce: - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce: Where LG is the leaving group; - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce: as well as - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

45. A method for synthesizing adagracib, the method comprising the following steps: - In the presence of acid and polar solvent, Reacts with phosgene derivatives to produce: - In the presence of a base and a polar aprotic solvent, and React to produce: - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce: Where LG is the leaving group; - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce: as well as - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

46. ​​A method for synthesizing adagracib, the method comprising the following steps: - In the presence of a base and a polar solvent, and reaction, to produce: - In the presence of acid and polar solvent, Reacts with phosgene derivatives to produce: - in the presence of an alkali metal salt of an alkoxide and a polar aprotic solvent, and React to produce: - in the presence of additives, polar aprotic solvents and bases, Reacts with an activator to produce: Where LG is the leaving group; - in the presence of (S)-2-(piperazin-2-yl)acetonitrile or an inorganic salt or organic salt thereof and one or more polar aprotic solvents, Reacts with base to produce: as well as - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

47. A method for synthesizing adagracib, the method comprising the following steps: a') in the presence of a base and a polar solvent, reacting a compound having the following structure: Reacts with compounds having the following structures: To produce the final compound of step (a') having the following structure:

48. The method of claim 47, wherein the base is an inorganic base.

49. The method of claim 48, wherein the inorganic base is selected from the group consisting of methoxide, ethoxide, isopropoxide, tert-butoxide, and tert-amyloxide, or ammonium or alkali metal salts thereof.

50. The method of claim 49, wherein the ammonium salt or alkali metal salt is selected from the group consisting of lithium, sodium and potassium.

51. The method of claim 49, wherein the inorganic base is sodium methoxide.

52. The method of claim 47, wherein the polar solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, NMP, and an alcohol having the formula R-OH, wherein R is alkyl, allyl, or aryl.

53. The method of claim 52, wherein the polar solvent is MeOH.

54. The method of claim 47, further comprising step (b'): b') reacting the final compound of step (a') with an alkylating agent or an arylating agent and a base in the presence of a polar solvent to produce a final compound of step (b') having the following structure: wherein R is methyl, ethyl, isopropyl or benzyl.

55. The method of claim 54, wherein the alkylating or arylating agent is selected from the group consisting of an aryl halide or alkyl halide RX (wherein R is methyl, ethyl, isopropyl or benzyl, and X is Cl, Br, I, alkyl sulfonate, aryl sulfonate, triflate or perfluorobutyl sulfonate), a dialkyl sulfate and a dialkyl carbonate.

56. The method of claim 55, wherein the alkylating agent is 2-iodopropane.

57. The method of claim 54, wherein the polar solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, NMP, and an alcohol having the formula R-OH, wherein R is alkyl, allyl, or aryl.

58. The method of claim 57, wherein the polar solvent is MeOH.

59. The method of claim 50, wherein the base is an inorganic base.

60. The method of claim 59, wherein the inorganic base is selected from the group consisting of hydroxides, carbonates, bicarbonates, and phosphates, or ammonium or alkali metal salts thereof.

61. The method of claim 60, wherein the ammonium salt or alkali metal salt is selected from the group consisting of lithium, sodium and potassium.

62. The method of claim 54, further comprising step (c'): c') reacting the final compound of step (b') with an oxidizing agent in the presence of a polar aprotic solvent and optionally a catalyst and a base to produce a final compound of step (c') having the following structure:

63. The method of claim 62, wherein the oxidizing agent is selected from the group consisting of peracids, potassium persulfate, bleach, hydrogen peroxide, and urea hydrogen peroxide.

64. The method of claim 63, wherein the oxidizing agent is hydrogen peroxide.

65. The method of claim 62, wherein the catalyst is selected from the group consisting of sodium tungstate, phenylphosphonic acid, and methyltrioctylammonium hydrogen sulfate.

66. The method of claim 65, wherein the catalyst is sodium tungstate.

67. The method of claim 62, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, 2-propanol, and NMP.

68. The method of claim 67, wherein the polar aprotic solvent is 2-propanol.

69. The method of claim 62, wherein the base is an inorganic base.

70. The method of claim 69, wherein the inorganic base is selected from the group consisting of methoxide, ethoxide, isopropoxide, tert-butoxide, and tert-amyloxide, or ammonium or alkali metal salts thereof.

71. The method of claim 70, wherein the ammonium salt or alkali metal salt is selected from the group consisting of lithium, sodium and potassium.

72. The method of claim 70, wherein the base is sodium methoxide.

73. The method of claim 63, further comprising step (d'): d') reacting the final product of step (c') with (S)-(1-methylpyrrolidin-2-yl)methanol in the presence of a base and a polar aprotic solvent to produce a final compound of step (d') having the following structure:

74. The method of claim 73, wherein the base is an alkoxide selected from the group consisting of isopropoxide, tert-butoxide and tert-amyloxide, or ammonium or alkali metal salts thereof.

75. The method of claim 74, wherein the alkali metal salt is selected from the group consisting of lithium, sodium and potassium.

76. The method of claim 74, wherein the alkoxide is potassium tert-butoxide.

77. The method of claim 73, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

78. The method of claim 77, wherein the polar aprotic solvent is THF.

79. The method of claim 73, further comprising step (e'): e') reacting the final product of step (d') with an activating agent in the presence of a base, an additive and a polar aprotic solvent to produce a final compound of step (e') having the following structure: Where LG is a leaving group.

80. The method of claim 79, wherein the activator is selected from the group consisting of sulfonyl halides R-SO2X (wherein R is tolyl, mesityl, nitrobenzenesulfonyl, methyl, ethyl or propyl, and X is F, Cl or Br), anhydrides (trifluoromethanesulfonic anhydride and nonafluorobutanesulfonic anhydride) and organic trifluoromethanesulfonate reagents R 1 -N-Tf2 (where R 1 is phenyl, 5-chloro-2-pyridine or 2-pyridine).

81. The method of claim 80, wherein the activating agent is bis(trifluoromethanesulfonyl)aniline.

82. The method of claim 81, wherein the base is an inorganic base.

83. The method of claim 82, wherein the inorganic base is selected from the group consisting of carbonates, bicarbonates and phosphates, or ammonium or alkali metal salts thereof.

84. The method of claim 83, wherein the inorganic base is tripotassium phosphate or dipotassium phosphate.

85. The method of claim 81, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

86. The method of claim 85, wherein the polar aprotic solvent is MeCN.

87. The method of claim 79, further comprising step (f'): f') reacting the final product of step (e') with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce a final compound of step (f') having the following structure:

88. The method of claim 87, wherein the base is an organic base.

89. The method of claim 88, wherein the organic base is selected from the group consisting of DIPEA, Et3N, DABCO and DBU.

90. The method of claim 87, wherein the base is an inorganic base.

91. The method of claim 90, wherein the inorganic base is selected from the group consisting of carbonates, bicarbonates and phosphates, or ammonium or alkali metal salts thereof.

92. The method of claim 91, wherein the inorganic base is tripotassium phosphate or dipotassium phosphate.

93. The method of claim 87, wherein the polar aprotic solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, and NMP.

94. The method of claim 93, wherein the polar aprotic solvent is MeCN.

95. The method of claim 87, further comprising step (g'): g') reacting the final compound of step (f') with sodium 2-fluoroacrylate (or the corresponding alkali metal salt or metal salt) and a coupling agent in the presence of a solvent and optionally a base to produce adagrasib.

96. The method of claim 95, wherein the coupling agent is selected from the group consisting of: propylphosphonic anhydride Carbonyldiimidazole (CDI), carbodiimide (e.g., dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), ethyl-(N',N'-dimethylamino)propylcarbodiimide hydrochloride (EDC.HCl)), phosphonium ((benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP)), and uronium (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU)).

97. The method of claim 95, wherein the solvent is selected from the group consisting of DMAc, DMF, 1,4-dioxane, THF, 2-MeTHF, MeCN, DMSO, DCM, EtOAc, IPAc, and NMP.

98. The method of claim 95, wherein the base is an organic base.

99. The method of claim 98, wherein the organic base is selected from the group consisting of DIPEA, Et3N, DABCO and DBU.

100. The method of claim 95, wherein the base is an inorganic base.

101. The method of claim 100, wherein the inorganic base is selected from the group consisting of carbonates, bicarbonates, and phosphates.

102. A method for synthesizing adagracib, the method comprising: In the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

103. A method for synthesizing adagracib, the method comprising the following steps: -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof, and a polar aprotic solvent, wherein LG is a leaving group, to produce: - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

104. A method for synthesizing adagracib, the method comprising the steps of: - in the presence of a base, an additive and a polar aprotic solvent, Reacts with an activator to produce: Where LG is the leaving group; -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce: - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

105. A method for synthesizing adagracib, the method comprising the steps of: - In the presence of a base and a polar aprotic solvent, Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol, wherein R is methyl, ethyl, isopropyl or benzyl, to produce: - in the presence of a base, an additive and a polar aprotic solvent, Reacts with an activator to produce: Where LG is the leaving group; -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce: - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

106. A method for synthesizing adagracib, the method comprising the steps of: - In the presence of a polar aprotic solvent, Reaction with an oxidizing agent, wherein R is methyl, ethyl, isopropyl or benzyl, to produce: - In the presence of a base and a polar aprotic solvent, Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce: - in the presence of a base, an additive and a polar aprotic solvent, Reacts with an activator to produce: Where LG is the leaving group; -make with a base, (S)-2-(piperazin-2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce: - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

107. A method for synthesizing adagracib, the method comprising the steps of: - In the presence of a polar solvent, Reaction with an alkylating agent or an arylating agent and a base to produce: wherein R is methyl, ethyl, isopropyl or benzyl; - In the presence of a polar aprotic solvent, Reacts with an oxidizing agent to produce: - In the presence of a base and a polar aprotic solvent, Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce: - in the presence of a base, an additive and a polar aprotic solvent, Reacts with an activator to produce: Where LG is the leaving group; -make With base, (S)-2-(piperazine -2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce: - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

108. A method for synthesizing adagracib, the method comprising the steps of: - In the presence of a base and a polar solvent, and reaction, to produce: - In the presence of a polar solvent, Reaction with an alkylating agent or an arylating agent and a base to produce: wherein R is methyl, ethyl, isopropyl or benzyl; - In the presence of a polar aprotic solvent, Reacts with an oxidizing agent to produce: - In the presence of a base and a polar aprotic solvent, Reaction with (S)-(1-methylpyrrolidin-2-yl)methanol to produce: - in the presence of a base, an additive and a polar aprotic solvent, Reacts with an activator to produce: Where LG is the leaving group; -make With base, (S)-2-(piperazine -2-yl)acetonitrile or an inorganic or organic salt thereof and a polar aprotic solvent to produce: - in the presence of a solvent and optionally a base, Reaction with 2-fluoroacrylic acid (or the corresponding alkali metal salt or metal salt) and a coupling agent to produce adagrasib.

109. A compound selected from the group consisting of:

Citation Information

Patent Citations

  • KRAS g12c inhibitors

    WO2019099524A1

Cited By

  • Synthesis method of adarglasib intermediate

    CN122010821A